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In recent years, despite the significant decline in number of malaria infections, 
malaria continues to be a threatening disease to humans with the emergence 
of artemisinin-resistant parasites. During the symptomatic, infection stage, 
malaria treatments rely on antimalarial chemotherapy to control the progress 
of infection. Hence, new drugs that can control infection and prevent 
transmission are urgently needed. In the early phase of drug discovery, 
metabolic modeling has been conducted to model growth at a genomic level 
and predict drug targets against Plasmodium falciparum, leading to the 
uncovering of 18 new predicted drug targets. However, those targets need to 
be verified by genetic or chemical target validation. Herein, two candidate drug 
targets; UMP-CMP kinase and dicarboxylate/ tricarboxylate carrier (DTC) 
protein were examined for necessity using gene knockouts by clustered 
regularly interspaced short palindromic repeats and Cas9 endonuclease-
mediated genome editing (CRISPR-Cas9). The gene disruption of both target 
loci along with the non-essential KAHRP gene was validated through 
genotyping analysis and confirmed by DNA sequencing. Subsequently, 
phenotypic analysis by microscopy implicated the essentiality of DTC and 
UMP-CMP kinase as, there were no visible viable parasites by thin blood 
smearing from transgenic parasites, while KAHRP2 transgenic parasites were 
observed on day 20 post-transfection.  However, quantitative RT-qPCR data 
is important to validate the visual observations; comparing with the KAHRP2 
transgenic cultures. Demonstrating essentiality of UMP-CMP kinase and DTC 
is the first step in targeting these proteins for future drug development. 
Furthermore, setting up the gene disruption system here could be applied to 
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Chapter 1 Introduction 
1.1 General information 
Malaria is a major tropical disease caused by a parasite in the genus 
Plasmodium. There are four well-established malaria parasites that infect 
humans. The two species that mainly infect humans, Plasmodium falciparum 
and Plasmodium vivax, are found in most endemic areas, while Plasmodium 
ovale and Plasmodium malariae are less commonly found in human cases and 
only have a sporadic and limited distribution (Snounou et al. 1993, Al-Maktari 
et al. 2003, Naing et al. 2014). Recently, the simian malaria parasites, 
Plasmodium cynomolgi and Plasmodium knowlesi, have been found in some 
cases of naturally acquired infection in humans; however, their transmission 
from human to human by an Anopheles mosquito has not been recorded 
(White 2008, Ta et al. 2014, Ahmed and Cox-Singh 2015). 
Malaria is found in tropical and sub-tropical regions. According to the World 
Malaria Report 2017, there were an estimated 216 million malaria infections 
globally (in 91 countries) causing 445,000 deaths in 2016. Infection by the 
virulent malaria parasite, P. falciparum, is predominant in sub-Saharan Africa 
and is responsible for 99% of all estimated malaria cases. Recently, although 
the number of malaria infections has significantly declined, malaria remains a 
threatening disease, particularly in children under 5 years of age residing in 
Africa. In addition, an emergence of artemisinin resistance has been reported 
along the Thailand-Myanmar border, leading to great concerns about malaria 
elimination programmes. Moreover, the effect of global warming may 
accelerate malaria spread; a temperature higher than 21°C is suitable for P. 
falciparum mating and maturation in the vector, placing an increasing 
proportion of the world population at risk of malaria infection (World Health 
Organization 2017)  
1.2 Malaria life cycle 
Malaria is caused by a protozoa parasite of Plasmodium spp. that has a 
complex multistage life cycle, with sexual reproduction in the Anopheles 
mosquito and an asexual reproductive stage within the red blood cells of the 
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human host (Figure 1.1). The sporozoite stage in the salivary glands of the 
mosquito is transmitted to a human host while the mosquito takes a blood 
meal. Once the sporozoite enters the host, within an hour the sporozoite 
invades the hepatocytes where then they replicate, divide, and transform into 
schizonts, which contain thousands of merozoites. Next, the infected 
hepatocytes rupture and the merozoites are released into the bloodstream, 
beginning the asexual reproductive stage. After the merozoites invade the 
erythrocytes, they envelop themselves within a layer that becomes a 
parasitophorous vacuole membrane when the invasion is complete. Over the 
subsequent 48 hours, P. falciparum parasites develop within the vacuole from 
trophozoites (ring-form) into schizonts that contain 12-16 daughter merozoites. 
The merozoites released from the erythrocytes invade fresh red blood cells to 
continue the cycle of parasite multiplication. In this stage, some parasites 
differentiate into gametocytes, which are the sexual form of the parasites. The 
transcription factor AP2G has been shown to regulate the gametocytogenesis 
transition (Kafsack et al. 2014). When a mosquito ingests the sexual form of 
parasites during a blood meal, fusion of the male and female gametes occurs 
in the stomach of the mosquito to form a zygote. Then the zygote elongates 
into an ookinete (a motile zygote). After that, the ookinete migrates across the 
midgut epithelium and develops into an oocyst. The oocyst undergoes a series 
of mitoses to form sporozoites. Once the oocyst has matured and ruptured, 
the sporozoites are released and they migrate to the mosquito salivary glands, 
where the parasites can infect a new host to complete its life cycle. 
 
Figure 1.1  The life cycle of Plasmodium spp. 
The malaria life cycle can be divided into 2 stages; the asexual stage in 
humans and the sexual stage in mosquitoes. The figure was taken from (de 
Koning-Ward et al. 2015).   
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1.3  Malaria treatment and drug resistance 
Throughout history, malaria fevers have been treated with herbal remedies, 
namely cinchona bark and qinghao. Then, quinine was isolated from cinchona 
bark in 1820 and used for malaria treatment as a pure chemical compound 
thereafter. However, the global quinine supply was cut off during World War II, 
inducing an effort to develop new synthetic antimalarial drugs. Eventually, a 
powerful antimalarial, chloroquine, was successfully synthesized in the 1940s 
and widely used throughout the world (Meshnick and Dobson 2001). 
Chloroquine was used as the first line treatment for two decades before the 
emergence of chloroquine-resistant parasites was reported from South 
America and South-East Asia in the early 1960s. Then, the P. falciparum 
resistance to chloroquine spread to Africa during the 1980s (D'alessandro and 
Buttiens 2001, Trape 2001). The mechanism of parasite resistance to 
chloroquine has been previously discussed. Mutations in the chloroquine 
resistance transporter (PfCRT) and multidrug resistance gene (pfmdr1), 
coding for the membrane transporter (PfMDR1), can contribute to chloroquine 
resistance in P. falciparum. Mutations occurring in both targets causes the 
concentration of chloroquine in the digestive vacuole to decrease 
considerably, allowing the parasites to avoid chloroquine drug pressure 
(Anderson et al. 2005, Cojean et al. 2006). Despite the widespread presence 
of chloroquine resistance, most countries in Africa are still using this drug as 
the first-line treatment since chloroquine is the cheapest antimalarial drug that 
is available on the market. Some areas (Malawi, Kenya, Botswana, and South 
Africa) use sulphadoxine-pyrimethamine (SP) instead of chloroquine 
(D'alessandro and Buttiens 2001). However, SP resistant parasites have also 
been identified. These drugs have a prolonged half-life, leading to selection of 
resistant parasite strains that have developed a mutation in the active site of 
the drug target (Triglia et al. 1997, Nzila et al. 2000, Mita et al. 2009).  
Another effective antimalarial drug, artemisinin, is the active ingredient that 
was extracted from a herb (sweet wormwood) and has been used to cure 
malaria infections since 1979. This compound was successfully synthesized 4 
years later and has been used as a first line treatment since then. Artemisinin 
is considered to be a fast-acting drug that rapidly reduces parasitaemia up to 
10000-fold every 48 hours (White 2008). Due to the occurrence of SP-resistant 
parasites, an alternative drug or new treatment regimen was urgently needed. 
Hence, artemisinin-based combination therapies (ACT) were implemented for 
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malaria treatment in all endemic countries. For combination therapy, 
artemisinin or artemisinin derivatives are used as a partner drug with other 
effective antimalarial drugs with an unrelated mode of action, such as 
lumefantrine, amodiaquine, mefloquine, piperaquine, or sulfadoxine-
pyrimethamine as first-line treatment of uncomplicated P. falciparum malaria 
(Guidelines for Treatment of Malaria Third Edition, World Health Organization, 
2015) (World Health Organization 2015) 
However, cases of uncomplicated P. falciparum infection with decreasing 
artemisinin susceptibility were reported in the Greater Mekong subregion in 
2009. The resistance of P. falciparum to artemisinin derivatives presents by 
delaying the rate of clearance of parasites after monotherapy (Dondorp et al. 
2009, Noedl et al. 2009). The mechanism of artemisinin resistance is still 
unclear. Pfkelch13 has been proposed as an excellent marker for artemisinin 
resistance in P. falciparum after genome sequencing of parasites isolated from 
a patient showed mutations in the K13 propeller protein (Ariey et al. 2014, 
Miotto et al. 2015). Moreover, enhancement of the cell stress response by the 
accumulation of ubiquitinated proteins and increases in proteasome activity 
have also been found in artemisinin-resistant parasites (Mbengue et al. 2015). 
The emergence of artemisinin resistance and simultaneous resistance to the 
partner drugs (summarised in Table 1.1) is a serious obstacle to artemisinin-
based combination therapies and the Global Malaria Eradication Programme 
(Phyo and Nosten 2018). Thus, there is an urgent need for new drugs that are 
safe to use and have novel modes of action against these resistant parasites. 
Because malaria treatment relies on antimalarial chemotherapy to control the 
parasites (Schlitzer 2007) and there are no effective malaria vaccines currently 
available (Cowman et al. 2016), target identification and validation are 










Table 1.1  Summary of the emergence of antimalarial resistant drugs 
 
The table was adapted from (Phyo and Nosten 2018).  
1.4 Target identification 
Approximately 5300 genes (that are highly conserved and probably have 
essential functions) are found in Plasmodium genomes (Janse et al. 2011); 
however, based on the information from P. falciparum and P. berghei, only 
around 500 genes have been investigated by gene disruption methods (de 
Koning-Ward et al. 2015). Therefore, the remaining genes need to be further 
studied in regards to their function. To narrow down the list of possible 
therapeutic targets, an in silico system has been implemented for prediction of 
antimalarial drug target candidates. Using a highly curated metabolic network 
model of P. falciparum, iFT342 was developed by Francis Isidore Garcia 
Totañes as part of his Ph.D. project at the University of Leeds in 2017 (Totanes 
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2017), identifying 18 novel drug targets. The constraint-based genome-scale 
model used flux analysis to solve for increasing biomass as a measure of 
growth and an in silico simulation of single gene knockout analysis to identify 
essential genes, resulting in a higher percentage of true positive predictions 
compared with other malaria models. 
1.5 Target validation 
Once a target has been identified, it then needs to be analysed for crucial 
biological functions. Validation techniques in Plasmodium parasites require a 
genetic manipulation approach (e.g., gene knockout or introduction of a 
transgene) to directly assess the function of the predicted gene target. The 
conventional gene knockout method is the most common technique in use for 
investigation of gene function in Plasmodium parasites. This method involves 
the introduction of foreign DNA into the malaria parasite using DNA 
transfection. The success of the conventional method depends upon 
recombination of homologous sequences between the engineered plasmid 
and the target genomic site via spontaneous single/double crossover of the 
homology regions. The appropriate targeting sequence and a good selection 
approach are necessary for success when performing crossing homologous 
recombination. Using circular plasmids for transfection usually results in the 
episomal plasmid being maintained rather than the integration event, 
introducing the requirement of another drug cycle or negative selection, which 
is time-consuming. Moreover, the stable transfectants require regular genetic 
monitoring because applying on/off drug pressure could lead to a naturally 
drug-resistant mutant. Also, homologous integration is a rare event and hence 
there is a very low efficiency of generating knockouts (Crabb and Cowman 
1996, Waterkeyn et al. 1999, Crabb et al. 2004). Given these limitations, the 
conventional gene knockout method is an inefficient and time-consuming 
technique. Therefore, there is a need for a robust and efficient technique to 
study gene function in malaria parasites. 
In the past decade, genetic tools for use with P. falciparum have developed 
considerably; for instance, the fusion of the gene of interest (GOI) to a 
destabilization domain (DD) or an Escherichia coli DHFR destabilizing domain 
(DDD) have been developed to control the expression of essential genes since 
the parasites often die after an indispensable gene is disrupted (Armstrong 
and Goldberg 2007, de Koning-Ward et al. 2015). Conditional knockout using 
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the dimerizable Cre (DiCre) system, has also been used for controlling the 
deletion of essential genes (Collins et al. 2013). However, these approaches 
do not improve the frequency of integration and are not suitable for large-scale 
gene deletion.   
More recently, a new system that utilizes programmable nucleases to make 
double-stranded breaks in the genome has been developed for improving the 
integration frequency along with site-specific modifications. It is well-known 
that a chromosome break is a catastrophic event in the cell, leading to cell 
death unless it can be repaired. By providing a donor DNA for homologous 
directed recombination, the cell can repair the broken-double strand through 
the insertion of the provided sequence, resulting in the genome being modified 
in any way desired. There are two techniques in current use that use a 
nuclease to induce targeted chromosome breaks in Plasmodium parasites: 
zinc finger nucleases (ZFNs) and the clustered regularly-interspaced short 
palindromic repeat (CRISPR) associated Cas9 protein (CRISPR-Cas9) 
system (Straimer et al. 2012, Ghorbal et al. 2014). 
ZFNs have a DNA binding domain (ZFN-L and ZFN-R) for DNA recognition 
and contain a catalytic domain of Fok1 for cleavage. The donor plasmid 
encoding a pair of ZFNs (ZFN-L and ZFN-R) is co-expressed using a single 
promoter of viral 2A ribosome skip peptide, allowing the individual polypeptides 
to be expressed. When the donor plasmid is transfected into malaria parasites, 
the pair of ZFNs is expressed and forms a dimer of ZFN-L and ZFN-R, resulting 
in the assembly of an artificial nuclease enzyme, which induces a double-
stranded DNA break in the genome at the specified target site. Subsequently, 
the broken DNA is repaired by homology-directed recombination using 
homologous regions provided from the donor plasmid due to the absence of a 
non-homologous end joining (NHEJ) system in Plasmodium spp. The use of 
this system has been successfully demonstrated in P. falciparum and the 
integrant parasites are detected after only 2 weeks; nevertheless, there are 
some disadvantages to this system. For example, it is costly and difficult to 
design ZFNs because of the high AT content of P. falciparum (Straimer et al. 
2012, Lee et al. 2014, Lee and Fidock 2014). 
The CRISPR-Cas9 system is a prokaryotic adaptive immune mechanism 
defence against viruses or other invading DNA. CRISPR associated with cas 
genes is involved in acquired immunity against the bacteriophages of 
Streptococcus thermophiles and was first described by Barrangou et al (2007). 
8	
	
They found a series of repeat sequences interspersed with short fragments of 
viral nucleic acid integrated into the bacteria cells that conferred resistance to 
phages (Barrangou et al. 2007). In 2008, Brouns et al. identified the mature 
CRISPR RNAs (crRNAs) associated with Cas protein from the host that was 
used to interfere with virus proliferation (Brouns et al. 2008). Then, Jinek et al. 
(2012) showed that a dual RNA structure composed of the mature crRNA base 
forms a duplex with the trans-activating tracrRNA and is crucial to direct the S. 
pyogenes type II Cas9 protein (spCas9) to cleave double-stranded DNA at the 
specific target DNA sequences in vitro (Jinek et al. 2012). 
Based on a programmable dual-RNA–guided DNA endonuclease in adaptive 
bacterial immunity of S. pyogenes, this system has been applied for gene 
editing in malaria parasites, first demonstrated by Ghorbal et al (2014). In this 
method, the parasites are transfected with two plasmids, one being the pUF1-
Cas9 plasmid that provides a Cas9 endonuclease for making the double-
strand break (DSB) in a site specific to the target DNA guided by the sgRNA, 
and the second being a plasmid (pL7-GOI) that contains the sgRNA and the 
donor DNA template for homology recombination. Regarding the pUF1-Cas9 
plasmid, a cas gene from S. pyogenes was engineered to express the 
endonuclease Cas9 bearing nuclear localization signals (NLS) on both sides 
of nuclease under the control of plasmodial regulatory element while the 
sgRNA in the CRISPR plasmid was transcribed through the U6 small nuclear 
(sn) RNA regulatory elements. Once the double-stranded DNA is broken by 
Cas9, the cell repairs itself via its endogenous repair mechanism using the 
insertion of the homologous sequences of interest provided on the transfected 
DNA vector (the donor DNA). Using this system, they also showed the 
integrated parasites were achieved within 8 days of transfection (Ghorbal et 
al. 2014).  
In the CRISPR plasmid constructed by this group, the original plasmid pL6 
eGFP can be modified to induce gene disruption in any targeted loci in P. 
falciparum by adapting the homology sequences and by introducing a new 
targeting sgRNA into the plasmid. The newly engineered plasmid is then co-
transfected with the unmodified Cas9 plasmid. Following a demonstration of 
the well-established CRISPR-Cas9 system in P. falciparum by Ghorbal et al 
(2014), this simple method is robust and has a high efficiency and precise 
integration into the target locus and could be a promising approach for large-
scale gene disruption. Thus, two potential drug targets (UMP-CMP kinase and 
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dicarboxylate/ tricarboxylate carrier protein) have been chosen for establishing 
the CRISPR-Cas9 system in our laboratory as a model, with plans to test other 
predicted malaria drug targets in the future. 
1.6 UMP-CMP kinase as a drug target for antimalarial chemotherapy 
The gene for UMP-CMP kinase (PF3D7_0111500, EC 2.7.4.14) contains 1116 
bp, encoding 371 amino acids, and is a bifunctional enzyme. It plays an 
important role in nucleic acid synthesis by converting UMP, CMP, and dCMP 
into their diphosphate form. In malaria parasites, UMP is the first pyrimidine 
nucleotide that acts as the precursor for all pyrimidine nucleotides 
biosynthesis. Then, these diphosphate forms are converted into UTP, CTP, 
dTTP and dCTP, which are essential for DNA and RNA synthesis (Krungkrai 
and Krungkrai, 2016). In humans, this enzyme is pivotal in some anticancer 
and antiviral therapies by converting nucleoside analogues into their 
triphosphorylated active form through a phosphorylation reaction (Liou et al. 
2002, Segura-Peña et al. 2004). A comparison of UMP-CMP kinase from 
various species (human, slime mould, yeast, pig, and mouse) showed that this 
enzyme is highly conserved, suggesting a crucial function of this kinase across 
species (Segura-Peña et al. 2004). For P. falciparum, it shares 44.79% identity 
with humans (Figure 1.2) and the active site of this enzyme is strongly 
conserved, corresponding to other species. Since UMP-CMP kinase is 
essential in anticancer treatment (leukaemia, lymphoma, and solid tumours) 
and the malaria parasite is also a highly proliferating organism, this enzyme 
could possibly be a target for antimalarial agents. 
In addition, the data from gene expression in P. falciparum (strain 3D7) using 
Illumina RNA-seq (López-Barragán et al. 2011) revealed that high expression 
of the UMP-CMP kinase gene is found in the late trophozoite and the schizont 
stages (as shown in Figure 1.3), stages characterized by having an 
exponential replication of parasites in red blood cells. Hence, cutting off 
production of nucleotides used for DNA and RNA synthesis could be a way to 
control the number of parasites. Moreover, high expression of this gene is also 
found in the sexual stages: gametocyte II, gametocyte v, and ookinete, 
suggesting it could also be a target for blocking or perturbing parasite 
transmission. UMP-CMP kinase is predicted to be a novel drug target with a 
potentially lethal effect by using the in silico simulation of single gene knockout 
analysis from metabolic modelling (iFT342). UMP-CMP kinase enzyme has 
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not been characterized in Plasmodium spp. until recently. We conclude that 




Figure 1.2 Homology and structure-based alignment of UMP-CMP 
kinase 
The structure- based sequence alignment compared between UMP-CMP 
kinase from P. falciparum (PF3D7_0111500) and human enzyme (1tev.1.A, 
short- form open conformation), was generated using the protein structure 
homology modelling server Swiss Model. Blue highlight depicts identical amino 




Figure 1.3 Gene expression of UMP-CMP kinase  
Transcript levels of fragments per kilobase of exon model per million mapped 
reads (FPKM) were obtained from the Illumina-based sequencing of P. 
falciparum 3D7 mRNA from two gametocyte stages (II and V), ookinete, and 
four time points of erythrocytic stages representing ring, early trophozoite, late 
trophozoite, and schizont. The expression level defines as numbers of reads 
per kilobase per million mapped reads. The percentile graph shows the ranking 
of expression of the PF3D7_0111500 gene compared to all others in this 





1.7 Dicarboxylate/tricarboxylate carrier (DTC) protein as a drug target 
for antimalarial chemotherapy 
Dicarboxylate/tricarboxylate carrier (PF3D7_0823900) is an integral 
membrane protein that is 318 amino acids long (957 bp). It belongs to the 
mitochondrial carrier protein family, which is responsible for the transportation 
of metabolites and cofactors across the inner membrane of mitochondria. This 
protein from P. falciparum has been expressed using a cell-free system and 
characterized by Nozawa et al (2011). They showed PfDTC is able to 
exchange oxoglutarate–malate, oxoglutarate–oxaloacetate, or oxoglutarate–
oxoglutarate in the artificial membrane (Nozawa et al. 2011). However, data 
from the in vivo experiment using 13C isotope-labelled mutant parasites 
showed that PfDTC does not import oxaloacetate into the mitochondria and 
instead is involved in mitochondrial α-ketoglutarate-malate transportation of 
tricarboxylic acid metabolism (Ke et al. 2015). A comparison of PfDTC with 
other mitochondrial membrane proteins from humans shows 32.62%, 21.38%, 
22.59%, and 22.80% identity with dicarboxylate carrier protein, mitochondrial 
2-oxodicarboxylate carrier isoform 1, tricarboxylate transport protein isoform a, 
and tricarboxylate transport protein isoform b, respectively (Figure 1.4). Hence, 
it is a good prospect for the development of parasite-specific inhibitors 
especially since there is high expression of the pfdtc gene in the late 
trophozoite stage (Figure 1.5). Blocking reproduction of parasites in the red 
blood cell stages is necessary for treatment of symptomatic disease. The 
highest level of expression of the pfdtc gene occurs in gametocyte II (López-
Barragán et al. 2011), which could be a good target for malaria elimination. 
PfDTC is predicted to have a growth limiting effect in metabolic modelling 
(iFT342) but gene disruption of pfdtc has not been previously performed. This 





Figure 1.4 Multiple amino acid sequence alignment of DTC 
Amino acid sequence alignment of DTC from P. falciparum compared with the 
mitochondrial membrane proteins from humans was generated using Clustal 
Omaga protein alignment. The accession number of the proteins: 
XP_001349285.1; Pf_DTC, CAB59892.1; Hs_DC, NP_085134.1; Hs_mito 
OxoC, NP_005975.1; Hs_TCT iso_A, NP_001243463.1; Hs_TCT iso_B. 
Abbreviations used in the figure: Pf; P. falciparum, Hs; Homo sapiens, DTC; 
Dicarboxylate/tricarboxylate carrier, DC; dicarboxylate carrier protein, mito 
OxoC; mitochondrial 2-oxodicarboxylate carrier isoform 1, TCT iso_A; 
tricarboxylate transport protein isoform a, TCT iso_B; tricarboxylate transport 
protein isoform b. (*) amino acid positions with identical residue, (:) amino acid 
positions with conserved substitution amino acid, (.) amino acid positions with 
semi-conserved substitution amino acid, and (non-marked) amino acid with 
non-conserved substitution amino acid. 
 
Pf_DTC           -MDRDIAKYDLESSSSVDVNKKGNNNKSVFEKIKPFAVGGASGMFATFCIQPLDMVKVRI 59 
Hs_DC            --------------------------MAAEARVSRWYFGGLASCGAACCTHPLDLLKVHL 34 
Hs_mito OxoC     ----------------MSAKP---EVSLVREASRQIVAGGSAGLVEICLMHPLDVVKTRF 41 
Hs_TCT iso_A     ------MPAPRAPRALAAAAPASG-KAKLTHPGKAILAGGLAGGIEICITFPTEYVKTQL 53 
Hs_TCT iso_B     MFPAALARRPRRPKSGTGEGPERQRPGGSLRSGFPVPAGGLAGGIEICITFPTEYVKTQL 60 
                                                       ** :.        * : :*.:: 
 
Pf_DTC           QLNAEGK--NVLRNPFIVAKDIIKNEGFLSLYKGLDAGLTRQVIYTTGRLGLFRTFSDMV 117 
Hs_DC            QTQQEVK--LRMT---GMALRVVRTDGILALYSGLSASLCRQMTYSLTRFAIYETVRDRV 89 
Hs_mito OxoC     QIQRCATDPNSYKSLVDSFRMIFQMEGLFGFYKGILPPILAETPKRAVKFFTFEQYKKLL 101 
Hs_TCT iso_A     QLDER-SHPPRYRGIGDCVRQTVRSHGVLGLYRGLSSLLYGSIPKAAVRFGMFEFLSNHM 112 
Hs_TCT iso_B     QLDER-SHPPRYRGIGDCVRQTVRSHGVLGLYRGLSSLLYGSIPKAAVRFGMFEFLSNHM 119 
                 * :   .               .: .*.:.:* *:   :  .      ::  :.   . : 
 
Pf_DTC           K-KEGEPLPFYKKCFCALAAGGLGAFI-GNPADLSLIRLQADNT--LPKELKRNYTGVFN 173 
Hs_DC            AKGSQGPLPFHEKVLLGSVSGLAGGFV-GTPADLVNVRMQNDVK--LPQGQRRNYAHALD 146 
Hs_mito OxoC     G-YVS-LSPALTFAIAGLGSGLTEAIV-VNPFEVVKVGLQANRNTFAEQPS---TVGYA- 154 
Hs_TCT iso_A     R-DAQGRLDSTRGLLCGLGAGVAEAVVVVCPMETIKVKFIHDQT--SPNPK---YRGFFH 166 
Hs_TCT iso_B     R-DAQGRLDSTRGLLCGLGAGVAEAVVVVCPMETIKVKFIHDQT--SPNPK---YRGFFH 173 
                               : .  :*   ..:   * :   : :  : .    :            
 
Pf_DTC           ALYRISK--EEGLFALWKGSVPTIARAMSLNLGMLSTYDQSKEFL--Q--KYLGVGMKTN 227 
Hs_DC            GLYRVAR--EEGLRRLFSGATMASSRGALVTVGQLSCYDQAKQRVLST--GYLSDNIFTH 202 
Hs_mito OxoC     --RQIIKKEGWGLQGLNKGLTATLGRHGVFNMVYFGFYYNVKNMIPVN--KDPILEFWRK 210 
Hs_TCT iso_A     GVREIVR--EQGLKGTYQGLTATVLKQGSNQAIRFFVMTSLRNWYRGDNPNKPMN-PLIT 223 
Hs_TCT iso_B     GVREIVR--EQGLKGTYQGLTATVLKQGSNQAIRFFVMTSLRNWYRGDNPNKPMN-PLIT 230 
                    .: :    **    .* . :  :        :    . ::                  
 
Pf_DTC           LVASVISGFFAVTLSLPFDFVKTCMQKMKADPVTKKMPYKNMLDCSIQLYKKGGISIFYS 287 
Hs_DC            FVASFIAGGCATFLCQPLDVLKTRL-------MNSKGEYQGVFHCAVETAKLGPLA-FYK 254 
Hs_mito OxoC     FGIGLLSGTIASVINIPFDVAKSRIQGPQP--VPGEIKYRTCFKTMATVYQEEGILALYK 268 
Hs_TCT iso_A     GVFGAIAGAASVFGNTPLDVIKTRMQGLEA------HKYRNTWDCGLQILKKEGLKAFYK 277 
Hs_TCT iso_B     GVFGAIAGAASVFGNTPLDVIKTRMQGLEA------HKYRNTWDCGLQILKKEGLKAFYK 284 
                    . ::*  :     *:*. *: :             *:   .      :   :  :*. 
 
Pf_DTC           SYATYYVRIAPHAMITLITVDYLNNLLKK-IS-- 318 
Hs_DC            GLVPAGIRLIPHTVLTFVFLEQLRKNFGIKVPS- 287 
Hs_mito OxoC     GLLPKIMRLGPGGAVMLLVYEYTYSWLQENW--- 299 
Hs_TCT iso_A     GTVPRLGRVCLDVAIVFVIYDEVVKLLNKVWKTD 311 
Hs_TCT iso_B     GTVPRLGRVCLDVAIVFVIYDEVVKLLNKVWKTD 318 





Figure 1.5 Gene expression of DTC 
Transcript levels of fragments per kilobase of exon model per million mapped 
reads (FPKM) were obtained from the Illumina-based sequencing of P. 
falciparum 3D7 mRNA from two gametocyte stages (II and V), ookinete, and 
four time points of erythrocytic stages representing ring, early trophozoite, late 
trophozoite, and schizont. The expression level defines as numbers of reads 
per kilobase per million mapped reads. The percentile graph shows the ranking 
of expression of the PF3D7_0823900 gene compared to all others in this 
experiment. The figure was taken from PlasmoDB (Plasmodium Genomic 
Resource). 
1.8 Research objectives 
The main objective of this study is to utilise the CRISPR-Cas9 system to 
genetically validate two candidate drug targets in malaria parasites that were 
predicted by our metabolic modelling. This research covers the specific 
objectives: 
1. Establish the CRISPR-Cas9 knockout system in our laboratory 
using the non-essential P. falciparum KAHRP gene as a positive 
control for the CRISPR-Cas9 system. 
2. Knock out UMP-CMP kinase and dicarboxylate/tricarboxylate 
carrier using the CRISPR-Cas9 system with negative controls for 
transfection. 
3. Analyse the target-gene disruptions using genotyping and confirm 
the integration by Sanger sequencing. 
4. Evaluate gene essentiality using quantitative RT-qPCR by 




Chapter 2 Methodology 
2.1 Identification of guide RNA sequences  
The sequences of the genes of interest (UMP-CMP kinase and DTC) and the 
entire genomic sequence of P. falciparum 3D7 were downloaded from 
PlasmoDB (Plasmodium Genomic Resource) to identify guide RNA 
sequences. The guide RNA sequence was designed according to the following 
characteristics: the single guide RNA (sgRNA) sequence must be 20 bases 
long, match the target-DNA site, and the sgRNA must be followed by a 
protospacer adjacent motif (PAM) sequence (5'-NGG-3'). The sgRNA 
sequence must start with a G (the RNA polymerase III-dependent U6 promoter 
requires a G at the 5' end of the RNA sequence to initiate transcription), and 
base 17 must either be an A or a T (Cas9 endonuclease will cleave 
approximately three bases upstream of the PAM). The sgRNA plus PAM 
sequence must only occur once in the whole genome (both in the sense and 
the antisense strands) to avoid off-target activity (Naito et al. 2014). The 
sgRNA sequence must have a GC content that is greater than or equal to 40%. 
According to the criteria above, two sequences of sgRNA, 
GAGTAAAGATCAACCCTTTGTGG and GGTGGATTAGGAGCCTTTATTGG 
were identified that were specific to UMP-CMP kinase and DTC, respectively. 
2.2 Designing primers for amplifying the homology regions  
The size of the amplified homology regions (HR) was restricted to 250–500 
bases in length and one of the homology regions must be close to the cutting 
site while the other homology region can be relatively far away. Based on the 
methodology of the In-Fusion cloning system (Takara Bio USA, Inc), the 
primers were designed with an adaptor sequence, which consists of 20 
nucleotides of homology with the target vector. For amplification of HR1 of 
UMP-CMP kinase, a pair of oligonucleotide primers was designed as: forward 
primer: 5'-CTTTCCGCGGGGAGGACTAG(TGATCA)ATGAATTACCAAAAG 
TTATT-3' and reverse primer: 5'-TTTTTTTACAAAATGCTTAAAAATTGTTT 
TTCCCAAATA-3', which generated a PCR product of 322 bp. The underlined 
sequences are the homology nucleotides (adaptor sequence) between the 
PCR product and the vector, which is necessary for In-fusion base cloning. 
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The restriction site of Bcll (represented in the bracket) was added to allow for 
further screening of positive clones and the bold sequences are the gene-
specific sequences. The primers for amplifying HR2 of UMP-CMP kinase were: 
forward primer: 5'-TATTTATTAAATCTAGAATT(TGATCA)GGATGGATTAAT 
ATAATAGG-3' and reverse primer: 5'-ATTATTTTTACCGTTCCATGTTACAT 
ATTTGTAAAAACATAC-3', which produced a 453 bp PCR product. 
Regarding DTC, two pairs of primers to amplify HR1 and HR2 were created 
using the same strategy: forward primer: 5'-
CTTTCCGCGGGGAGGACTAG(TGATCA)ATGGACAGAGATATAGCTAA-
3' and reverse primer: 5'-TTTTTTTACAAAATGCTTAAGTTCTCCTTCTTTTT 
TTACC-3', which amplified a 413 bp PCR product of HR1 while forward primer: 
5'-TATTTATTAAATCTAGAATT(TGATCA)CCTGCAGATTTATCTTTAA-3' 
and reverse primer: 5'-ATTATTTTTACCGTTCCATGTTGAATAGAACAATCT 
AACAT-3', were designed for amplification of HR2 of DTC with a product size 
of 436 bp. 
2.3 Cloning of CRISPR plasmids and insertion of guide RNA 
sequences 
In this study, plasmid pL6 eGFP (Figure 2.1) was obtained from Prof. Jose-
Juan Lopez-Rubio (Biology of Host-Parasite Interactions Unit, Institut Pasteur, 
Paris, France). It was used as the template plasmid for generating CRISPR 
plasmids. Cloning of HR fragments and guide RNA sequences of GOI into the 
plasmid pL-6 eGFP to generate pL7 GOI plasmids was performed by replacing 
the GFP regions (GFP 5' and GFP 3') with the homology regions (HR1 and 
HR2) of GOI. The guide RNA sequences were then replaced at the BtgZI 
adapter region (as illustrated in Figure 2.2). The multiple cloning steps were 







Figure 2.1 An illustration of the pL6 eGFP plasmid  
The original plasmid pL6 eGFP used as the template plasmid for generating 





Figure 2.2 The overall procedure for construction of the CRISPR 
plasmids  
The plasmid pL7 GOI was generated from the plasmid pL6 eGFP by replacing 
the GFP regions (GFP 5’ and GFP 3’) with the homology regions (HR1 and 
HR2) of GOI, then the targeting-oligonucleotides of sgRNA were added at the 
BtgZI adapter region. All cloning steps were performed by using the In-Fusion 
HD Cloning Kit (Takara Bio USA, Inc). Then, the presence of the insertion and 







2.3.1 Genomic DNA extraction 
Genomic DNA was used as a temple for amplifying the homology region of the 
GOIs. To extract genomic DNA, the unsynchronized parasite P. falciparum 
strain 3D7 at 4% parasitaemia was cultured in a T75 flask and then pelleted 
by centrifugation at 3,000 rpm for 10 minutes. The cell pellet was then 
resuspended by adding a 5x pellet volume of sterile PBS buffer, gently mixing 
it, and adding a saponin solution at a final concentration of 0.15% to lyse the 
human red blood cells, then incubated at room temperature for 2 minutes with 
gentle mixing. To stop the reaction, PBS buffer was added to obtain a final 
volume of 30 ml. After transferring the solution into an Oakridge tube and 
centrifugation at 10,000 rpm for 10 minutes, the supernatant was discarded. 
Then 700 ul of lysis buffer (10mM Tris-HCl, 20mM EDTA, and 1% SDS) was 
added to the parasite pellet and mixed gently. Subsequently, 10 µl of RNase 
A (10 mg/ml) was added and incubated at 37°C for 1 hour. After that, 10 µl of 
Proteinase K (18.2 mg/ml) was added and incubated overnight at 50°C to 
digest the proteins and non-nucleic acid cellular components. Then, 700 µl of 
a mixture of phenol: chloroform: isoamyl alcohol (25:24:1) was added and 
gently mixed by inverting to separate the protein contaminants and cellular 
debris into the organic phase, followed by centrifugation at 13,000 rpm for 10 
minutes. The isolated DNA in the aqueous phase was transferred into a clean 
1.5 ml microcentrifuge tube. To increase the purity of genomic DNA, this step 
was repeated again. Before adding ethanol to precipitate the DNA, 700 µl of 
hydrated diethyl ether was added into the aqueous solution to clean up the 
organic compounds from the isolated DNA. This was followed by centrifugation 
at 13,000 rpm for 10 minutes. The top layer of ether was discarded and then 
repeated this step again to increase the 260/230 absorbance ratio. After 
centrifugation, the aqueous phase in the bottom portion was transferred into a 
sterile 1.5 ml microcentrifuge tube and a 1/10 volume of 3M sodium acetate 
pH 5.2 was added. Then, 2 volumes of absolute ethanol were added and 
incubated at −20°C for 30 minutes to precipitate the DNA. After centrifugation 
again at 13,000 rpm for 10 minutes, the supernatant was removed and the 
pellet was washed with 70% ethanol and centrifuged it again. The next step 
was removing the supernatant and allowing the DNA pellet to dry. Then the 
DNA was dissolved in nuclease-free water and the DNA concentration was 




2.3.2 Amplification of homology regions 
To optimise the PCR conditions for amplification of the homology regions (HR), 
the reaction was performed in 10 µl mixture reaction, contained 10 ng of gDNA 
template (P. falciparum strain 3D7), 500 nM of the forward primer, 500 nM of 
the reverse primer, 1× of Q5® High-Fidelity 2X Master Mix and the final volume 
was adjusted with sterile water. The PCR reaction was performed for 30 
cycles; the first cycle consisted of the initial denaturation at 98°C for 30 
seconds; the subsequent 10 cycles consisted of 98°C for 10 seconds, 52°C for 
30 seconds, and 62°C for 30 seconds; followed by 20 cycles consisting of 98°C 
for 10 seconds, 62°C for 1 minutes and 62°C for 2 minutes. The optimised 
PCR condition here was applied for all HR amplifications except HR2 of UMP-
CMP kinase. In order to obtain the expected band from HR2 of UMP-CMP 
kinase, the extension temperature was optimised from 62°C to 65°C while the 
other temperatures remained the same. The final large-scale PCR reaction 
was performed in a volume of 100 µl and followed the procedures as described 
above, then the amplified HR fragment was purified by using a gel extraction 
kit (QIAquick, catalogue no. 28704) and stored at −20°C.  
 
2.3.3 Cloning the homology region into the pL6 eGFP plasmid 
The original plasmid pL6 eGFP was digested with SpeI and AflII to remove the 
GFP 5', where the purified fragment of HR1 was introduced into the plasmid. 
For the backbone plasmid preparation, a total of 5 µg of plasmid was used for 
the digestion reaction by separating it into 5 reactions. Each 50 µl reaction 
contained 1 µg of plasmid, 5 µl of the 10× CutSmart buffer, 0.5 µl each of the 
two restriction enzymes, and the rest of the volume was adjusted using sterile 
water. The mixture solution was then incubated at 37° for at least 2 hours. The 
digested reaction was further cleaned up by using a PCR purification kit 
(QIAquick, catalogue no. 28104). In this study, cloning of HR1 into the plasmid 
was performed by using the In-Fusion cloning kit. The 10 µl In-Fusion reaction 
contained 100 ng of digested plasmid, the amount of insert fragment that gave 
a 1:10 molar ratio of vector and insert, 2 µl of In-Fusion HD enzyme premix, 
and sterile water. An online NEB ligation calculator 
(https://nebiocalculator.neb.com/#!/ligation) used to calculate the required 
amount of the insert fragment that gave a 1:10 molar ratio of vector and insert. 
Then the In-Fusion cloning reaction was incubated at 50° for 15 minutes.  
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Subsequently, the heat shock method was used to transform the recombinant 
plasmid from the In-Fusion reaction into Escherichia coli XL10 gold 
ultracompetent cells. The 2.5 µl of In-Fusion reaction was incubated with 50 µl 
of competent cells on ice for 30 minutes then applied a heat-pulse in a 42°C 
water bath for 30 seconds, followed by a 2 minute- incubation on ice. Then, 
250 µl of LB broth was added into the transformation reaction and incubated 
at 37°C with shaking at 200 rpm for 1 hour for plasmid amplification. After that, 
the transformants were plated on LB agar supplemented with 100 µg/ml 
ampicillin and incubated overnight at 37°C. After that, plasmid extraction from 
a single colony was verified by Sanger sequencing before cloning of the HR2 
fragment into the plasmid.  
The pL6 plasmid carrying the HR1 fragment was then digested with EcoRI and 
NcoI to remove the original GFP 3' and replace it with the HR2 of GOI. The 
digestion reaction was performed as described above. For the cloning step, a 
ratio of 1:10 of digested plasmid and HR2 fragment was used in the In-Fusion 
reaction, then the transformation protocol followed all of the steps as described 
for the HR1 cloning. Colonies were selected from transformants of the In-
Fusion reaction, then the insertion of HR2 and its correctness were confirmed 
by Sanger sequencing. 
 
2.3.4 Insertion of guide RNA sequences into the pL6 plasmid 
The annealed oligonucleotides of sgRNA were introduced into the pL6 plasmid 
carrying HR1 and HR2 of GOI by replacing them at the BtgZI adapter region 
(Figure 2.2) through the use of the In-Fusion cloning kit. According to the 
requirements of In-Fusion based cloning, the oligonucleotides were designed 
with adaptor sequences (20 nucleotides of homology with the target vector). 
The oligonucleotides of sgRNA that were specific to UMP-CMP kinase were 
designed: Oligo 1: CATATTAAGTATATAATATTGAGTAAAGATCAACCCTT 
TGTGGGTTTTAGAGCTAGAAATAGC and Oligo 2: GCTATTTCTAGCTCTA 
AAACCCACAAAGGGTTGATCTTTACTCAATATTATATACTTAATATG. The 
underlined sequences are adaptor sequences and the bold sequences 
represent the sgRNA that was identified for UMP-CMP kinase. The 




AGCTAGAAATAGC and Oligo 2: GCTATTTCTAGCTCTAAAACCCAATAAA 
GGCTCCTAATCCACCAATATTATATACTTAATAT, created using the same 
strategy as for UMP-CMP kinase.  
To insert the sgRNA into the plasmid, the annealing of oligonucleotides was 
performed by following this procedure: the annealing reaction contained 10 µl 
of the plus strand oligonucleotides and 10 µl of the minus strand 
oligonucleotides (at a 100 µM concentration) and 2.2 µl of NEB buffer 2 in a 
sterile PCR tube. Consequently, the annealing program consisted of step 1, 
heating at 95°C for 10 minutes; followed by step 2, repeated 95°C, 1 segment, 
then in the step 3 the reaction was gradually cooled with a reduction of 
0.6°C/second for 16-times. After that, in step 4, it was held at 85°C for 1 minute, 
repeated 85°C, 1 segment in step 5, followed by step 6 with a reduction of 
0.6°C/second for 16-times. Then in step 7, 75°C for 1 minute, repeated 75°C, 
1 segment in step 8 and gradually cooled with a reduction of 0.6°C/second for 
16-times in step 9, then repeated the same cycle until reaching 25°C in step 
22, ended with 25°C for 1 minute. After that, the reaction was held at 4°C. The 
annealed oligonucleotides (45 µM) were placed on ice and then were diluted 
to 500 nM in cold 5 mM Tris buffer pH 8.0. The oligonucleotides duplex was 
stored in a −20°C freezer. 
Cloning of the oligonucleotides duplex of sgRNA into the pL6 plasmid (carrying 
HR1 and HR2 of GOI), the backbone plasmid was prepared in parallel by 
digestion with BtgZI. The digestion reaction was performed in 20 µl reaction 
(in a total of 5 reaction tubes), contained 1 µg of plasmid, 2 µl of the 10× 
CutSmart buffer, 0.5 µl of restriction enzyme BtgZI, and the final volume was 
adjusted to 20 µl with sterile water. The reaction was incubated at 60°C for 1 
hour, then 0.5 µl of additional restriction enzyme was added and incubated for 
another hour at the same temperature to ensure that the plasmid was 
completely digested. Subsequently, the digested reaction was cleaned up by 
using a PCR purification kit. Then, the In-Fusion reaction was performed in a 
10 µl reaction containing 100 ng of digested plasmid, 1.5 µl of annealed 
oligonucleotides (concentration 500 nM), 2 µl of In-Fusion HD enzyme premix 
and the final volume was adjusted with sterile water, then the mixture was 
incubated at 50° for 15 minutes. Consequently, the In-Fusion reaction was 
transformed into E. coli XL10 gold ultracompetent cells by following the 
procedure as described in the section of cloning the homology region into the 
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pL6 eGFP plasmid. Plasmid extractions were performed and confirmed the 
insertion of sgRNA by Sanger sequencing. 
 
2.3.5 Plasmid extraction by the alkaline extraction method 
The plasmids after extraction by the alkaline extraction method from the 
transformants were screened for the insertion of HR1 and HR2 by digestion 
with the restriction enzyme BclI. To isolate the plasmid, 5 ml of bacterial culture 
was centrifuged at 3,000 rpm for 10 minutes, then 100 µl of Solution I (25 mM 
Tris-HCl pH 8.0, 10 mM EDTA, 50 mM glucose and 150 µg/ml RNase A) was 
added to the cell pellet and mixed by vortexing. After that, 150 µl of Solution II 
(0.2 M NaOH and 1% SDS) was added and mixed by inverting 6–8 times, then 
the sample was left at room temperature for 2 minutes followed by adding 150 
µl of 3 M sodium acetate pH 5.2 and inverting 6–8 times. Then, it was 
centrifuged at 13,000 rpm for 10 minutes. The supernatant was transferred into 
a sterile 1.5 ml microcentrifuge tube and 1 volume of a mixture of phenol: 
chloroform: isoamyl alcohol (25:24:1) was added into the DNA sample, mixed 
by inverting, then centrifuged at 13,000 rpm for 10 minutes. The aqueous 
phase containing the isolated DNA was then transferred into a clean 1.5 ml 
microcentrifuge tube and the DNA was precipitated by adding 1/10 volume of 
3M sodium acetate pH 5.2. Then, 2 volumes of absolute ethanol were added 
and it was incubated at −20°C for 30 minutes, followed by centrifugation at 
13,000 rpm for 10 minutes, removal of the supernatant, and washing the DNA 
pellet with 70% ethanol. After that, the supernatant was gently removed and 
the DNA was dried. The DNA pellet was then dissolved in sterile water and the 
DNA concentration was measured by using a Nanodrop spectrophotometer. It 
was then stored at −20°C. 
2.4 Parasite culture and transfection 
2.4.1 Maintenance parasite culture 
Asexual blood–stage P. falciparum parasites (strain 3D7) were cultured in 
RPMI1640 growth medium (with L-glutamine, HEPES and phenol red, Life 
Technologies) supplemented with 5 g/L Albumax II (Gibco), 2 g/L sodium 
bicarbonate (Sigma), 0.1 g/L hypoxanthine (Sigma) and 0.1% (v/v) gentamicin 
(10 mg/ml, Gibco) at 5% haematocrit. Human red blood cells (O+ blood was 
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obtained from the National Blood Service of the National Health Service Blood 
and Transplant Unit (NHSBT) Seacroft, Leeds) was washed with RPMI 
medium by centrifugation at 3,000 rpm for 10 minutes, then the supernatant 
was discarded and repeated this step three times to remove the serum, dead 
cells, and white blood cells prior to use. The packed red blood cells were then 
mixed with an equal volume of RPMI medium to achieve a 50% haematocrit.  
The parasite cultures were grown in 25 cm2 polystyrene non-vented tissue 
culture flasks (SARSTEDT) and individually gassed with a 1% oxygen, 3% 
carbon dioxide, and 96% nitrogen gas mixture for 10 seconds prior to sealing 
the flasks. The culture flasks were then incubated horizontally in a 37°C 
incubator. The medium was changed daily by tilting the culture flask for 30–45 
minutes to allow the red blood cells to settle on the bottom corner of the flask 
and then carefully removing the medium by a transfer pipette. After that, pre-
warmed medium was added into the flask and the culture was then gassed 
and sealed before placing it back into the 37°C incubator. 
The total number of parasites was monitored by blood smearing. While the 
culture flask was tilted, a sample of blood was collected by transfer pipette and 
smeared on a glass slide. The blood smear was then fixed with 100% methanol 
for 30 seconds and stained with 10% Giemsa staining solution (VWR 
Chemicals), diluted in Sorensen's buffer (10 mM NaH2PO4, 28 mM Na2HPO4, 
pH 7.2) for 10 minutes. The slide was rinsed with tap water and air dried before 
reading by Olympus BH-2 light microscopy with oil-immersion (1000× 
magnification).  
The parasite counting was performed by using a Miller graticule, a device that 
assists in counting that is installed in the microscope eyepiece. The Miller 
graticule (Figure 2.3) consists of two squares, an outer square (in blue) and an 
inner square (in red). The inner square represents a tenth of the whole area of 
the graticule field (the outer square). Fields of distributed red blood cells were 
used for counting where the graticule was placed. The inner square was 
counted, then used to estimate the total number of red blood cells in the 
graticule field by multiplying by 10. The total number of infected red blood cells 
was also counted in both the inner and outer square for the parasitaemia 
calculation. The parasitaemia was calculated according to Equation 1 . It 
should be noted that in the case of multiple infections, the infected red blood 
cells were only counted as one and the stages of parasites were also noted. 




total number of infected red blood cells 
estimated total number of red blood cells 
The parasite subculturing was performed when the parasitaemia exceeded 4% 
by diluting with 5% haematocrit in fresh complete medium to reduce the 
parasitaemia to 0.5 to 1%. The formula that was used for subculturing (a final 
volume of 6 ml per flask) is illustrated below:  
 
                                  Vi = 6 ml × (Pf/Po) 
                                 Vmedium = 0.9 × (6 ml − Vi) 
                                 VRBC = 0.1 × (6 ml − Vi) 
Where: 
Po = initial parasitaemia 
Pf = final parasitaemia 
Vi = volume of sample from initial culture 
Vmedium = volume of fresh medium 





Figure 2.3 An illustration of a Miller graticule  
The inner square (in red) represents a tenth of the whole area of the outer 
square (in blue). By counting red blood cells in the small square and then 
multiplying that number by 10, we can make an estimation of the total number 
of red blood cells in the whole graticule field. 
Parasitaemia  = X	100%					Equation	1	
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2.4.2 Preparation of parasites for transfection 
The early ring stage with a parasitaemia between 8–10% was used for 
transfection because the ring parasites tolerate electroporation better as 
compared with the other stages. A synchronised culture was prepared as 
described below by sorbitol treatment to get rid of any parasites at other stages 
than the ring stage. Prior to transfection, the parasites were cultured as 
described above until the parasitaemia reached 5–6% and the majority of the 
parasites were in the ring stage. The parasite culture (total volume 6 ml) was 
then transferred into a 50 ml Falcon tube and centrifuged at 3,000 rpm for 5 
minutes. The medium was discarded and replaced with a 0.5× culture volume 
of filter-sterilised 5% sorbitol (3 ml of 5% sorbitol was added). In this step, the 
parasite pellet was gently mixed with a transfer pipette to ensure that the 
infected red cells were completely resuspended. The parasites were incubated 
in sorbitol for 10 minutes at room temperature and then a 2.5× culture volume 
(15 mL) of pre-warmed RPMI complete medium was added to dilute the 
concentration of sorbitol, followed by centrifugation at 3,000 rpm for 5 minutes. 
The supernatant was removed and replaced with 6 ml of pre-warmed complete 
medium, then the culture was transferred to a new culture flask, gassed and 
sealed before placing it back in an incubator. After synchronisation, the 
parasites were fed twice a day and the 24 hour synchronized parasites were 
assessed if the synchronisation was successful by blood smearing. The 
parasites were expected to be about 90–95% mid trophozoites. The early ring 
parasites had formed at 42 hours post-synchronisation. To obtain a highly 
synchronous ring stage parasites, a second synchronisation can be performed 
40–42 hours later.  
 
2.4.3 Plasmid preparation 
Five plasmids, pL7-UMP-CMP kinase, pL7-DTC, pL7-KAHRP, pL7-KAHRP2, 
and pUF1-Cas9 were used in this study. The two plasmids pL7-KAHRP and 
pUF1-Cas9 were a gift from Prof. Jose-Juan Lopez-Rubio while the another 
KAHRP plasmid called pL7-KAHRP2 was obtained from Dr. Francis Isidore 
Garcia Totañes. The pL7-KAHRP2 plasmid was constructed in order to reduce 
the size of plasmid (1.1 kb smaller than the pL7-KAHRP). All plasmids were 
transformed into E. coli XL10 gold ultracompetent cells and kept in glycerol 
stock at −70°C. For plasmid preparation, the glycerol stocks were scraped and 
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cultured in 100 ml of LB broth supplemented with 100 µg/ml ampicillin with 
shaking at 200 rpm at 37°C for 16 hours. The bacterial cells were transferred 
into a 50 ml Falcon tube and harvested by centrifugation at 3,000 rpm, 4°C for 
30 minutes. The plasmids were then isolated using a ZymoPURE™ Plasmid 
Midiprep Kit (catalogue number: D4200), following the manufacturer's 
protocol. According to the transfection protocol, 60 µg of circular plasmid or 10 
µg of linearized plasmid are required for transfection of P. falciparum (Ghorbal 
et al. 2014). The circular plasmids were re-precipitated by adding 1/10 volume 
of 3M sodium acetate pH 5.2. Then, 0.7 volumes of isopropanol were added 
and it was incubated at −20°C for 30 minutes to precipitate the DNA. After 
centrifugation at 13,000 rpm for 10 minutes, followed by removing the 
supernatant gently, the pellet was washed with 70% ethanol and centrifuged 
again. The ethanol was removed without perturbing the pellet, then the DNA 
was dried. This step was conducted in a sterile cabinet to avoid any plasmid 
contamination. The DNA was dissolved in sterile water and stored at −20°C. 
The DNA concentration was measured by using a Nanodrop 
spectrophotometer. 
For the linearization, the plasmids were digested with the restriction enzyme 
HinCII (2 cutting sites in the yFCU cassette). The 150 µl reaction included 3 
µg of plasmid, 15 µl of 10× NEB buffer 3.1, 1.5 µl of restriction enzyme HinCII 
(10 U/µl) and adjusted to the final volume with sterile water. The reaction was 
then incubated at 37°C for at least 2 hours. A total of 7 linearized reactions 
from each plasmid was performed in order to obtain sufficient DNA for the 
transfection experiment. After digestion, the linearized DNA was purified by 
adding 1 volume of the phenol-chloroform mixture solution and subsequently 
centrifuging at 13,000 rpm for 10 minutes. The top layer was transferred into a 
sterile 1.5 ml microcentrifuge tube and the DNA was then re-precipitated as 
described above for circular plasmid precipitation. The linearization was 
verified on agarose gel electrophoresis. The DNA was dissolved in sterile 
water at an appropriate concentration and stored at −20°C. 
 
2.4.4 Transfection 
For the co-transfection of the pUF1-Cas9 plasmid and the pL7-GOI linear 
plasmids, the transfection procedure followed the previously described 
protocol. The two plasmids were simultaneously transfected into the 
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synchronized early ring stage parasites (around 8% parasitaemia). First, the 
synchronized culture was packed by centrifugation at 3,000 rpm for 5 minutes, 
then suspended in a 7.5 packed cell volume of ice-cold cytomix buffer. After 
that, 0.8 ml of the suspended infected cells were transferred into the 4 mm 
electroporation cuvette and kept on ice. Then 60 µg of pUF1-Cas9 circular 
plasmid and 10 µg of the linear plasmid were added into the cuvette (the 
maximum volume added that contained the two plasmids was 30 µl), mixed 
gently and electroporated using the conditions: 0.62 kV, 25 µF and 200 Ω 
resistance in a BioRad Gene Pulser II. After incubation of the electroporated 
cells on ice for 2 minutes, the cells were then transferred into a culture flask 
containing 6 ml of complete medium and 5% freshly washed red blood cells. 
The transfected parasite flask was gassed before culturing in the 37°C 
incubator. Drug selection was applied with 1.5 nM WR99210 and 300 µM 
DSM265 24 hours after transfection and maintained for 5 days. The media 
cultures were changed daily and the parasites were continuously monitored 
until the appearance of transgenic parasites was detected by Giemsa-stained 
thin blood smear.   
In the co-transfection for the circular plasmids, the protocol obtained from the 
Pasteur Institute was used in this experiment. The overall protocol for 
introducing CRISPR-Cas9 plasmids into the parasites and verifying the 
presence of transgenic parasites is summarised in Figure 2.4. The transfection 
should be completed within 30–45 minutes. Therefore, the procedure was 
followed step by step as shown below: 
1) Plasmids 
Added 60 µg of pUF-Cas9 and 60 µg of each CRISPR (pL7) plasmid, and 270 
µL of cytomix buffer (120 mM KCl, 0.15 mM CaCl2, 2 mM EGTA, 5 mM MgCl2, 
25 mM HEPES, 10 mM K2HPO4, 10 mM KH2PO4, pH 7.6) into a sterile 1.5 ml 
microcentrifuge tube and incubated the DNA solution at 37°C. The mixture was 
conducted in the safety cabinet. 
2) Culture flasks 
Prepared a 6 ml pre-warmed complete RPMI medium mixed with 100 µl of 






The parasites in the early ring stage with parasitaemia between 8–10% were 
pelleted using centrifugation at 3,000 rpm for 5 minutes and the supernatant 
was gently removed by a transfer pipette. Then the pellet was kept in the 
cabinet prior to transfection. 
4) Electroporation 
The DNA/cytomix buffer in the sterile 1.5 ml microcentrifuge tube was removed 
from the incubator and added with 100 µl of infected RBC pellet, mixed well, 
and transferred this mixture into the 2 mm electroporation cuvette (Geneflow, 
catalogue number: E6-0060). This step was done carefully to avoid any 
bubbles. The total volume in a 2 mm cuvette was 400 µl. The parasites were 
then electroporated using the conditions 0.31 kV, 25 µF and 200 Ω resistance 
using a BioRad Gene Pulser II. After the pulse, the time constant was recorded 
in milliseconds. Then, the cells were transferred into the pre-prepared culture 
flask that contained complete medium and fresh RBCs. The cuvette was rinsed 
with medium to collect any remaining cells, then the parasite flask was gassed 
and placed back in the 37°C incubator. Three hours after the transfection, the 
medium was changed to remove the cytomix and replaced it with the pre-
warmed fresh medium. Drug selection with 1.5 nM WR99210 and 300 µM 
DSM265 was applied 6 hours post-transfection. The next day, the medium was 
changed and adjusted the haematocrit to 5%. The culture flasks were mixed 
twice a day to increase the invasion rate. For the next 5–8 days, the culture 
flasks had their media changed daily and the parasitaemia was monitored on 
a daily basis until no live parasites were observed in the blood smears. The 
drug selection was performed for only 5 days post-transfection. Afterwards, the 
medium was changed every 2 days, but gassing of the cultures was performed 
every day. Seven days post-transfection 3 mL of parasite culture was collected 
for genomic DNA extraction and replaced it with 3 mL of 5% haematocrit 
complete RPMI medium into the culture flasks. Fresh RBCs were added to the 
cultures every 2 weeks and continued to monitor the haematocrit. The 
transgenic parasites were continuously monitored for 60 days post-





Figure 2.4 The overall protocol of CRISPR/Cas9 system 
The synchronized ring-stage parasites were transfected with the 
CRISPR/Cas9 plasmids, then the transfected parasites were cultured under 
drug pressure for 5 days to select the parasites that contained the two 
plasmids. After that, genomic DNA isolation was performed (7 days of post-
transfection) using the standard phenol-chloroform extraction method, then the 
integrated parasites were evaluated through genotyping and confirmed the 
gene modification by Sanger sequencing. 
 
2.5 Analysis of transgenic parasites 
The genomic DNAs were isolated from 3 ml of parasite cultures using the 
protocol for gDNA extraction as described in Section 2.3.1. These genomic 
DNAs were used for genotyping to evaluate the CRISPR success (whether the 
donor DNA (hdhfr) was incorporated into the target locus). Based on the 
CRISPR-Cas9 system, after the site specific DNA was cleaved by Cas9 
endonuclease, the cleaved target locus was then repaired by homology 
recombination through the using of HR1 and HR2 flanking hdhfr, resulting in 
hdhfr to be incorporated into the genome. Therefore, the primers for the 
diagnostic PCR of the 5' and the 3' integrations were generated by designing 
the outer primers as being only genomic DNA specific without including any of 
the HR sequence to avoid amplifying the plasmid. The inner primers were 
donor DNA (hdfhr) specific. A diagram of the primer design is depicted in 
Figure 2.5. Melting temperatures of the primers around 54–59°C were chosen 
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(more specific binding was expected from higher melting temperature primers). 
Ideally, the diagnostic primers are expected to amplify only the integrated 
mutant-specific sequences whereas the wild-type parasites and the episomal 
mutant parasites are expected to produce no product.  
For genotyping, the PCR reactions were performed in a 20 µl mixture reaction, 
containing 10–20 ng of gDNA, 500 nM of forward primer, 500 nM of reverse 
primer, 10 µl of Q5® High-Fidelity 2X Master Mix and the final volume was 
adjusted with sterile water. The PCR reaction was performed for 40 cycles; the 
first cycle consisted of the initial denaturation at 98°C for 30 seconds and the 
subsequent 40 cycles consisted of 98°C for 10 seconds, the annealing 
temperature was adjusted (depending on the pair of primers in the reaction) 
and was performed for 30 seconds, then the extension temperature was held 
at 62°C for 2 minutes, followed by 62°C for 2 minutes and the temperature was 
then held at 4°C after final step. The PCR products were monitored by agarose 
gel electrophoresis and visualized under a UV transilluminator.  
To confirm the hdhfr cassette was integrated into the target locus, the obtained 
PCR products at the expected sizes were cloned into bacterial cells using the 
TOPO® TA Cloning® Kit (Invitrogen) for subsequent sequencing after gel 
purification of the PCR product. The TOPO® TA cloning® kit requires 3' A-
overhangs that can be added by the Taq polymerase. Therefore, the Q5-PCR 
product in this experiment had to be purified by using a gel extraction kit 
(QIAquick, catalogue no.28704) to remove the Q5®-High Fidelity DNA 
polymerase and to get rid of any non-specific bands. For the 3' A-overhangs 
addition, a 20 µl reaction containing 10 µl of purified PCR product and 10 µl of 
Go Taq Green 2x Master Mix was incubated at 72°C for 15 minutes using a 
PCR machine. After that, a TOPO® cloning reaction was performed in a 6 µl 
reaction, contained 4 µl of PCR product (after adding the 3' A-overhangs), 1 µl 
of salt solution (provided from the TOPO® TA Cloning® Kit) and 1 µl of TOPO® 
vector, and the mixture solution was incubated for 5 minutes at room 
temperature. Subsequently, the TOPO® cloning reaction was transformed into 
E. coli XL10 gold ultracompetent cells by adding 2 µl of the TOPO®cloning 
reaction to 50 µl of competent cells, then incubated on ice for 30 minutes 
followed by application of a heat-pulse in a 42°C water bath for 30 seconds, 
followed by 2 minutes of incubation on ice. After that, 250 µl of LB broth was 
added into the transformation reaction and it was incubated at 37°C with 
shaking at 200 rpm for 1 hour. The transformants were plated on LB agar 
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supplemented with 100 µg/ml ampicillin and incubated overnight at 37°C. 
Then, plasmid extractions were performed and confirmed the insertion of the 
hdhfr cassette by Sanger sequencing. Due to the multistep of sub-cloning 
through the TOPO® TA Cloning® Kit, some of the obtained PCR products at 





Figure 2.5 An illustration of the primers designed for genotyping 
The outer primers are genomic DNA specific and the inner primers are hdhfr 





Chapter 3 Result 
3.1 Cloning of the CRISPR plasmid and insertion of the guide RNA 
sequences targeting the UMP-CMP kinase 
To investigate the gene function of the UMP-CMP kinase, the plasmid pL7-
UMP-CMP kinase that contains sgRNA and the donor DNA template was 
generated from the plasmid pL6 eGFP, then this plasmid was used for co-
transfection with the unmodified pUF1-Cas9 plasmid to knockout the targeted 
gene in P. falciparum. Construction of the pL7-UIMP-CMP kinase plasmid was 
started by cloning of HR1 into the GFP 5’ region of the pL6 eGFP plasmid. The 
genomic DNA was extracted from the P. falciparum strain 3D7 by the standard 
phenol-chloroform extraction method and used as a template for the 
amplification of HR1. The fragment of HR1-UMP-CMP kinase was successfully 
amplified with a single band at the expected size of 322 bp as shown in Figure 
3.1 A. Then, a large-scale PCR reaction was performed and purified by a gel 
extraction kit before cloning this fragment into the plasmid pL6 eGFP. After the 
purification, the PCR product was monitored on an agarose gel (Figure 3.1 B), 
compared with the reference size 336 bp of the non-SERCA-type Ca2+- 
transporting P-ATPase gene. 
                           A                                               B 
                                                    
Figure 3.1 Amplification of HR1-UMP-CMP kinase  
(A) The PCR product of HR1- UMP-CMP kinase on 2% agarose gel 
electrophoresis, Lane 1: PCR product of HR1- UMP-CMP kinase using gDNA 
as a template (expected size 322 bp), Lane 2: negative control PCR reaction 
without the HR1- UMP-CMP forward primer, Lane 3: negative control PCR 
reaction without the HR1- UMP-CMP reverse primer, Lane 4: negative control 
PCR reaction without the gDNA template, Lane 5: positive control PCR 
reaction using the primers for amplification of non-SERCA-type Ca2+ -
transporting P-ATPase gene (expected size 336 bp). (B) HR1- UMP-CMP 
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kinase on 2% agarose gel electrophoresis after gel purification, Lane 1: the 
purified fragment of HR1 (322 bp), Lane 2: the reference size (336 bp) of the 
non-SERCA-type Ca2+- transporting P-ATPase gene. 
 
For the cloning of the HR1- UMP-CMP kinase into the plasmid, the plasmid 
pL6 eGFP was digested with SpeI and AflII to remove the GFP 5’, the site 
where the purified fragment of HR1 was introduced into the plasmid. The 
expected bands of 9496 bp and 347 bp were obtained after digestion, 
indicating that the plasmid was successfully digested by the restriction 
enzymes (Figure 3.2). After that, a 1:10 ratio of digested plasmid and HR1-
UMP-CMP kinase fragment were used for the In-Fusion cloning, then they 
were transformed into E. coli XL10 gold ultracompetent cells. Consequently, 
the transformants were plated on LB agar supplemented with 100 µg/ml 
ampicillin. Five clones of the transformants were picked up for plasmid 
extraction and the positive clones were then screened by digestion with BclI 
(since the restriction site of this enzyme was added into the forward primer for 
the positive clone screening). Due to the absence of this restriction site in the 
template plasmid, after enzyme digestion the positive clones would show a 
shifted band when compared with the undigested plasmid (the migration of the 
linearized plasmid is slower than the circular plasmid) as shown in Figure 3.3 
after digestion with BclI. It was difficult to see the shifted band after the 
digestion among the five selected clones, however, four of them (clones HR1-
U2, HR1-U3, HR1-U4 and HR1-U5) presented a slightly shifted band. 
Therefore, those plasmids were then subjected to DNA sequencing to confirm 
the presence of the HR1-UMP-CMP kinase and the correctness of its 
sequence. It was noted that for further experiments, screening for the positive 







Figure 3.2 Plasmid pL6-eGFP as a backbone for cloning of HR1-UMP-
CMP kinase 
The pL6 eGFP was digested with SpeI and AflII and analysed on 0.6% agarose 
gel electrophoresis, then it was used as the backbone for cloning of HR1.  Lane 
1: undigested plasmid pL6-eGFP, Lane 2: digested plasmid pL6-eGFP with 





Figure 3.3 Positive clone screening of HR1-UMP-CMP kinase 
Five plasmids were extracted from bacterial cells using the alkaline extraction 
method and those plasmids were then digested with BclI to check the insertion 
of HR1-UMP-CMP kinase. The positive clone was expected to have a shifted 
band when comparing digested parental plasmid with clones.  
From the DNA sequencing results, the DNA sequence from the selected 
clones was analysed by multiple sequence alignment compared with the 
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sequence of UMP-CMP kinase extracted from PlasmoDB (Gene ID: 
PF3D7_0111500). The alignment result is illustrated in Figure 3.4, where all 
four selected clones had the DNA sequence of HR1-UMP-CMP kinase as 
expected. The correct clone HR1-U5 (named pL6 HR1-U5) with a good 
chromatogram result was chosen for the further cloning of the HR2 of UMP-
CMP kinase. 
The next step of cloning was the insertion of the HR2 fragment into the plasmid 
pL6 HR1-U5. The amplification of the HR2-UMP-CMP kinase followed the 
same procedures as used for the HR1-UMP-CMP kinase. However, the 
expected PCR product was obtained with non-specific bands (Figure 3.5 A). 
To amplify a single PCR product, the PCR conditions were optimised by 
changing the extension temperature from 62°C to 64°C and 65°C. As a 
property of Q5® High-Fidelity DNA Polymerase, the annealing temperature 
must be followed as calculated by the NEB Tm Calculator 
(https://tmcalculator.neb.com/#!/main). Hence, only the extension temperature 
can be adjusted. After increasing the extension temperature, a single band of 
the PCR product was achieved from both temperatures (Figure 3.5 B); 
however, the extension temperature of 64°C showed a greater yield when 
compared to 65°C. This condition was therefore applied in the large-scale 
PCR. Consequently, the obtained HR2 fragment from the large-scale reaction 
was purified by gel purification and monitored on agarose gel electrophoresis 
as depicted in Figure 3.6, lane 3. The fragment of HR2-UMP-CMP kinase was 





Figure 3.4 Sequence alignment of HR1-UMP-CMP kinase 
DNA sequencing of the selected clones were compared with the UMP-CMP 
kinase sequence from PlasmoDB (Gene ID: PF3D7_0111500) using Clustal 
multiple sequence alignment. The red bold sequence represents the sequence 




CLUSTAL multiple sequence alignment by MUSCLE (3.8) 
 
                                                 
UMP-CMP kinase           CTAAATATATATCCAATGGCCCCTTTCCGCGGGGAGGACTAGTGATCAATGAATTACCAA 
HR1_U2                   -------------------------------NNNNNNNGNANNGATN-ATGAATTACCAA 
HR1_U4                   -------------------------------NNNNNNNNNANNGATN-ATGAATTACCAA 
HR1_U3                   ---------------------------------NNNNNNNANNNNTC-ATGAATTACCAA 
HR1_U5                   -------------------------------NNNNNNNNNNTNNGTTCATGAATTACCAA 
                                                                     *  ************ 
 
UMP-CMP kinase           AAGTTATTTTTAATATTTTTTTTTATGTTCATAGTAAAAAATCCATATTTGTTTGTCGAA 
HR1_U2                   AAGTTATTTTTAATATTTTTTTTTATGTTCATAGTAAAAAATCCATATTTGTTTGTCGAA 
HR1_U4                   AAGTTATTTTTAATATTTTTTTTTATGTTCATAGTAAAAAATCCATATTTGTTTGTCGAA 
HR1_U3                   AAGTTATTTTTAATATTTTTTTTTATGTTCATAGTAAAAAATCCATATTTGTTTGTCGAA 
HR1_U5                   AAGTTATTTTTAATATTTTTTTTTATGTTCATAGTAAAAAATCCATATTTGTTTGTCGAA 
                         ************************************************************ 
 
UMP-CMP kinase           AATTTCTACCTTTTAAAAAATAGCAAGCATTTTCCTTTTTACATAAATAGAACTAATGGT 
HR1_U2                   AATTTCTACCTTTTAAAAAATAGCAAGCATTTTCCTTTTTACATAAATAGAACTAATGGT 
HR1_U4                   AATTTCTACCTTTTAAAAAATAGCAAGCATTTTCCTTTTTACATAAATAGAACTAATGGT 
HR1_U3                   AATTTCTACCTTTTAAAAAATAGCAAGCATTTTCCTTTTTACATAAATAGAACTAATGGT 
HR1_U5                   AATTTCTACCTTTTAAAAAATAGCAAGCATTTTCCTTTTTACATAAATAGAACTAATGGT 
                         ************************************************************ 
 
UMP-CMP kinase           TCTTATAAAAAGGAACAACCTTTTAAAATTGAAAGCCAACATTATAATAAAATAACAAGA 
HR1_U2                   TCTTATAAAAAGGAACAACCTTTTAAAATTGAAAGCCAACATTATAATAAAATAACAAGA 
HR1_U4                   TCTTATAAAAAGGAACAACCTTTTAAAATTGAAAGCCAACATTATAATAAAATAACAAGA 
HR1_U3                   TCTTATAAAAAGGAACAACCTTTTAAAATTGAAAGCCAACATTATAATAAAATAACAAGA 
HR1_U5                   TCTTATAAAAAGGAACAACCTTTTAAAATTGAAAGCCAACATTATAATAAAATAACAAGA 
                         ************************************************************ 
 
UMP-CMP kinase           AAATTTTATAAATTTAAGAAAAATATATACACATCTACATCAAACTTTTCTATAAACAGT 
HR1_U2                   AAATTTTATAAATTTAAGAAAAATATATACACATCTACATCAAACTTTTCTATAAACAGT 
HR1_U4                   AAATTTTATAAATTTAAGAAAAATATATACACATCTACATCAAACTTTTCTATAAACAGT 
HR1_U3                   AAATTTTATAAATTTAAGAAAAATATATACACATCTACATCAAACTTTTCTATAAACAGT 
HR1_U5                   AAATTTTATAAATTTAAGAAAAATATATACACATCTACATCAAACTTTTCTATAAACAGT 
                         ************************************************************ 
                                            
UMP-CMP kinase           TATAATATTTGGGAAAAACAATTTTTAAGCATTTTGTAAAAAAAATTAAAATATATTTAT 
HR1_U2                   TATAATATTTGGGAAAAACAATTTTTAAGCATTTTGTAAAAAAAATTAAAATATATTTAT 
HR1_U4                   TATAATATTTGGGAAAAACAATTTTTAAGCATTTTGTAAAAAAAATTAAAATATATTTAT 
HR1_U3                   TATAATATTTGGGAAAAACAATTTTTAAGCATTTTGTAAAAAAAATTAAAATATATTTAT 
HR1_U5                   TATAATATTTGGGAAAAACAATTTTTAAGCATTTTGTAAAAAAAATTAAAATATATTTAT 
                         ************************************************************ 
 
UMP-CMP kinase           ATAATATTATTTTATTTTATTATATATTATATTATTTTTATTTTTATTTTTATTTTTTTT 
HR1_U2                   ATAATATTATTTTATTTTATTATATATTATATTATTTTTATTTTTATTTTTATTTTTTTT 
HR1_U4                   ATAATATTATTTTATTTTATTATATATTATATTATTTTTATTTTTATTTTTATTTTTTTT 
HR1_U3                   ATAATATTATTTTATTTTATTATATATTATATTATTTTTATTTTTATTTTTATTTTTTTT 
HR1_U5                   ATAATATTATTTTATTTTATTATATATTATATTATTTTTATTTTTATTTTTATTTTTTTT 
                         ************************************************************ 
 
UMP-CMP kinase           TCTCTACAAATTTTATCTATTGGTTTATTATAAAAATATCTATTTCTAATAATAAATAAT 
HR1_U2                   TCTCTACAAATTTTATCTATTNNTTTATTATAAAAATATCTATTTCTAATAATAAATAAT 
HR1_U4                   TCTCTACAAATTTTATCTATTGGTTTATTATAAAAATATCTATTTCTAATAATAAATAAT 
HR1_U3                   TCTCTACAAATTTTATCTATTGGTTTATTATAAAAATATCTATTTCTAATAATAAATAAT 
HR1_U5                   TCTCTACAAATTTTATCTATTGGTTTATTATAAAAATATCTATTTCTAATAATAAATAAT 
                         *********************  ************************************* 
 
UMP-CMP kinase           TAAGATATCAATTTATAGAAACAAAATATATACTTGTATAATTTTATTTTTTTATATAAA 
HR1_U2                   TAANATATCAATTTATANAAACAAAATATATACTTNTATAATTTTATTTTTTTATATAAA 
HR1_U4                   TAANATATCAATTTATANAAACAAAATATATACTTGTATAATTTTATTTTTTTATATAAA 
HR1_U3                   TAAGATATCAATTTATAGAAACAAAATATATACTTGTATAATTTTATTTTTTTATATAAA 
HR1_U5                   TAAGATATCAATTTATAGAAACAAAATATATACTTGTATAATTTTATTTTTTTATATAAA 
                         *** ************* ***************** ************************ 
 
UMP-CMP kinase           TCATTACATATATAATTATACAATATTTTTTCTAAGAGATAATTATATATTAATATATAT 
HR1_U2                   TCATTACATATATAATTATACAATATTTTTTCTAANAAATAATTATATATTAATATATAT 
HR1_U4                   TCATTACATATATAATTATACAATATTTTTTCTAANANATAATTATATATTAATATATAT 
HR1_U3                   TCATTACATATATAATTATACAATATTTTTTCTAAGAGATAATTATATATTAATATATAT 
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                      A                                                       B 
                                    
Figure 3.5 Amplification of HR2-UMP-CMP kinase  
(A) PCR product of HR2-UMP-CMP kinase on 2% agarose gel 
electrophoresis, using the extension temperature at 62°C, Lane 1: PCR 
product of HR2- UMP-CMP kinase using gDNA as a template (expected size 
453 bp), Lane 2: negative control PCR reaction without the HR2- UMP-CMP 
forward primer, Lane 3: negative control PCR reaction without the HR2- UMP-
CMP reverse primer, Lane 4: negative control PCR reaction without gDNA, 
Lane 5: positive control PCR reaction using the primers for non-SERCA-type 
Ca2+-transporting P-ATPase gene (expected size 336 bp). (B) PCR product of 
HR2 of UMP-CMP kinase on 2% agarose gel electrophoresis after adjusting 
the extension temperature, Lane 1: PCR product of HR2-UMP-CMP kinase 
using an extension temperature at 64°C, Lane 2: PCR product of HR2- UMP-
CMP kinase using an extension temperature at 65°C.  
 
For the backbone preparation, the plasmid pL6 HR1-U5 was digested with 
EcoRI and NcoI to remove the original GFP 3’ and replace it with the fragment 
of the HR2-UMP-CMP kinase. The expected fragments of the backbone 
plasmid were obtained after digestion, but undigested plasmids were also 
observed (Figure 3.6, lane 2). The cloning of the HR2-UMP-CMP kinase 
fragment into the digested pL6 HR1-U5 plasmid was performed by using the 
In-Fusion cloning kit. Thirteen clones from the transformants were picked up 
for plasmid extraction and sent for Sanger sequencing. Four of them, clones 
HR2-U9, HR2-U11, HR2-U12, and HR2-U13, had the sequence of the HR2-
UMP-CMP kinase, but the deletion of one adenine base was found in clone 
HR2-U12. The multiple sequence alignment of the sequencing clones was 
compared with the sequence of the UMP-CMP kinase from the database as 
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shown in Figure 3.7. From the sequencing data (shown in the appendix), clone 
HR2-U9 (named pL6 HR2-U9) had the expected sequence with a good 




Figure 3.6 Plasmid pL6 HR1-U5 as a backbone for cloning of HR2- UMP-
CMP kinase  
The plasmid pL6 HR1-U5, carrying the fragment of HR1-UMP-CMP kinase 
was digested with restriction enzymes EcoRI and NcoI and then the digested 
plasmid was used as the backbone plasmid for cloning of the HR2-UMP-CMP 
kinase fragment. The DNA fragments were analysed on 0.6% agarose gel 
electrophoresis. Lane 1: undigested plasmid pL6 HR1-U5, Lane 2: digested 
plasmid pL6 HR1-U5 with EcoRI and NcoI (expected bands were 9509 bp and 





Figure 3.7 Sequence alignment of HR2-UMP-CMP kinase 
DNA sequencing of the selected clones were compared with the UMP-CMP 
kinase sequence from PlasmoDB (Gene ID: PF3D7_0111500) using Clustal 
multiple sequence alignment. The red bold sequence represents the sequence 
and the position of the primer used for DNA sequencing. 
 
In the final step of cloning the plasmid pL7–UMP-CMP kinase, the 
oligonucleotides duplex of sgRNA (targeting the UMP-CMP kinase) was 
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inserted into the pL6 HR2-U9 plasmid (the CRISPR plasmid carrying the two 
fragments of HR1 and HR2 UMP-CMP kinase) by replacing the BtgZI adaptor. 
The backbone plasmid pL6 HR2-U9 after digested with the restriction enzyme 
is shown in Figure 3.8. The results show that the backbone plasmid was 
successfully digested into a single fragment, then the annealed 
oligonucleotides of sgRNA were inserted into the digested plasmid through the 
use of an In-Fusion cloning kit. After cloning and transformation of the In-
Fusion reaction into bacterial cells, four clones were selected from the 
transformants to confirm the insertion of sgRNA. Three of them showed the 
presence of sgRNA with the correct sequence inserted into the plasmid at the 
expected site. The DNA analysis by multiple sequence alignment is 
demonstrated in Figure 3.9. 
In summary, the pL7-UMP-CMP kinase carrying the sgRNA and the donor 
DNA template (hdhfr) flanked by two homology regions (HR1 and HR2) was 
successfully constructed and confirmed by Sanger sequencing. This plasmid 
was then co-transfected along with the plasmid pUF1-Cas9 into the malaria 




Figure 3.8 Plasmid pL6 HR2-U9 as a backbone for adding sgRNA of 
UMP-CMP kinase 
The pL6 HR2-U9 plasmid, carrying the two fragments of HR1 and HR2 UMP-
CMP kinase was digested with the restriction enzyme BtgZI and then the 
digested plasmid was used as the backbone plasmid for insertion of sgRNA. 
The DNA fragments were analysed on 0.6% agarose gel electrophoresis. Lane 
1: undigested plasmid pL6 HR2-U9, Lane 2: digested plasmid pL6 HR2-U9 




Figure 3.9 Sequence alignment of sgRNA-UMP-CMP kinase 
DNA sequencing of three clones were compared with the predicted sequence 
of sgRNA-UMP-CMP kinase using Clustal multiple sequence alignment. The 
predicted sequence was generated by using APE plasmid editor. The red bold 
sequence represents the sequence and the position of the primer used for 
DNA sequencing. 
 
3.2 Cloning of the CRISPR plasmid and insertion of guide RNA 
sequences targeting the dicarboxylate/tricarboxylate carrier (DTC) 
The fragment of HR1 from the DTC kinase was amplified from the genomic 
DNA and cloned into the template plasmid (pL6 eGFP). The fragment of HR1 
was successfully amplified with a single band as an expected size of 413 bp 
(Figure 3.10 A). Then, a large-scale PCR reaction was performed and cleaned 
up using a gel purification kit. After that, the purified fragment was cloned into 
the digested pL6 eGFP plasmid. The preparation of the backbone plasmid 
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(pL6 eGFP) by digestion with the restriction enzymes SpeI and AflII to remove 
GFP 5’ was performed in parallel. The fragments of plasmids after digestion 
and the purified PCR product of HR1 are illustrated in Figure 3.11 lane 1 and 
lane 2, respectively. The results show that the digested fragments were 
obtained as the expected sizes but undigested plasmids were also found, 
indicating that the reaction showed incomplete digestion. However, this 
digested backbone plasmid was subsequently used in the In-Fusion cloning 
reaction for cloning the fragment of HR1 into the plasmid. After cloning and 
transformation, three clones were selected and subjected to DNA sequencing 
to confirm the presence of HR1-DTC and the correctness of its sequence. 
From DNA analysis by multiple sequence alignment compared with the 
sequence of DTC from the database (Figure 3.12), two clones (HR1-DTC3 and 
HR1-DTC4) that had the expected sequence of HR1-DTC (the DNA 
sequencing data is shown in the appendix) were identified. Then the clone 
HR1-DTC4 (named pL6 HR1-DTC4) was selected as the template for cloning 
HR2-DTC. 
Cloning of the HR2-DTC fragment into the plasmid pL6 HR1-DTC4, the 
fragment of HR2-DTC that was amplified from genomic DNA with the expected 
size (436 bp) was obtained as illustrated in Figure 3.10 B. In the cloning step, 
the template plasmid pL6 HR1-DTC4 was also prepared in parallel by digestion 
with the restriction enzymes EcoRI and NcoI for removing the GFP 3’ and 
replacing it with the HR2-DTC fragment. The expected bands of the digested 
plasmid and the purified fragment of HR2-DTC were verified on agarose gel 
electrophoresis (Figure 3.11, Lane 4 and lane 5). For the plasmid digestion, 
although the fragments with the expected sizes were obtained, incomplete 
digestion was also observed. After that, a 1:10 ratio of digested plasmid and 
insert fragment was applied in the In-Fusion cloning, followed by 
transformation into bacterial cells. A total of 10 clones from the transformants 
were selected for plasmid extraction, then the plasmids were sent for DNA 
sequencing to confirm successful cloning. From the sequencing results, only 
clone HR2-DTC7 (named pL6 HR2-DTC7) had the correct sequence of HR2-
DTC when aligned with the DTC sequence, which was extracted from 
PlasmoDB (Figure 3.13). It should be noted that three of ten clones showed 
the sequence of the GFP 3’ (the backbone plasmid sequence) while the other 
clones showed failure of DNA sequencing with multiple peaks. In the final step 
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of cloning, the plasmid pL6 HR2-DTC7 was used as the template for insertion 
of the sgRNA.  
The backbone plasmid (pL6 HR2-DTC7) for adding the sgRNA was prepared 
through its digestion with the restriction enzyme BtgZI. The DNA fragment after 
digestion is illustrated in Figure 3.11, lane 7. The results showed successful 
digestion with a single band when compared with the undigested plasmid. 
Then, the annealed oligonucleotides of sgRNA (targeting DTC) were inserted 
into the digested plasmid using the In-Fusion cloning kit and the obtained 
plasmids from the In-Fusion reaction were transformed into E. coli XL10 gold 
ultracompetent cells. Eleven clones were subjected to DNA sequencing, and 
two of them, clone sgDTC7 and sgDTC8, were confirmed to have the 
oligonucleotides sgRNA sequence inserted into the plasmid (the DNA 
sequencing data is shown in the appendix) whereas the other clones failed to 
read the DNA sequencing. DNA analysis by multiple sequence alignment was 
performed as depicted in Figure 3.14, and both clones had the expected 
sequence of sgRNA targeting DTC and the sgRNA was inserted at the 
corresponding site as predicted. 
In summary, the plasmid pL7-DTC was successfully constructed and 
confirmed to be correct by Sanger sequencing. The gene function of DTC for 
parasite survival was then further investigated by co-transfection of the 
plasmid pL7-DTC and pUF1-Cas9 into the ring-stage parasites of P. 
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Figure 3.10 Amplification of HR1-DTC and HR2-DTC 
(A) PCR product of HR1-DTC on 1.5% agarose gel electrophoresis, Lane 1: 
PCR product of HR1-DTC using gDNA as a template (expected size 413 bp), 
Lane 2: negative control PCR reaction without the HR1-DTC forward primer, 
Lane 3: negative control PCR reaction without the HR1-DTC reverse primer, 
Lane 4: negative control PCR reaction without gDNA, Lane 5: positive control 
PCR reaction using the primers for amplification of non-SERCA-type Ca2+ -
transporting P-ATPase gene (expected size 336 bp). (B) PCR product of HR2- 
DTC on 1.5% agarose gel electrophoresis, Lane 1: PCR product of HR2- DTC 
using gDNA as a template (expected size 436 bp), Lane 2: negative control 
PCR reaction without the HR2-DTC forward primer, Lane 3: negative control 
PCR reaction without the HR2-DTC reverse primer, Lane 4: negative control 
PCR reaction without gDNA, Lane 5: positive control PCR reaction using the 
primers for amplification of non-SERCA-type Ca2+-transporting P-ATPase 








Figure 3.11 The backbone plasmids and the insert fragments HR1 and 
HR2 of DTC 
The plasmid pL6-eGFP was digested with SpeI and AflII, then it was used as 
the backbone for cloning of HR1 while the plasmid pL6 HR1-DTC4 was used 
as the template for cloning of HR2 after digested with EcoRI and NcoI. The 
DNA fragments were analysed on 0.6% agarose gel electrophoresis. Lane 1: 
digested plasmid pL6-eGFP with SpeI and AflII (expected bands, 9496 bp and 
347 bp), Lane 2: HR1 homology fragment (413 bp) of DTC after gel extraction, 
Lane 3: undigested plasmid pL6 HR1-DTC4, Lane 4: digested plasmid pL6 
HR1-DTC4 with EcoRI and NcoI (expected bands, 7274 bp, 2326 bp and 273 
bp), Lane 5: HR2 homology fragment (436 bp) of DTC after gel extraction, 
Lane 6: undigested plasmid pL6 HR2-DTC7, Lane 7: digested plasmid pL6 








Figure 3.12 Sequence alignment of HR1- DTC 
DNA sequencing of two clones were compared with the DTC sequence from 
PlasmoDB (Gene ID: PF3D7_0823900) using Clustal multiple sequence 
alignment. The red bold sequence represents the sequence and the position 





Figure 3.13 Sequence alignment of HR2-DTC 
DNA sequencing of the selected clone was compared with the DTC sequence 
from PlasmoDB (Gene ID: PF3D7_0823900) using Clustal multiple sequence 
alignment. The red bold sequence represents the sequence and the position 




Figure 3.14 Sequence alignment of the sgRNA-DTC 
DNA sequencing of two clones were compared with the predicted sequence of 
sgRNA-DTC using Clustal multiple sequence alignment. The predicted 
sequence was generated by using APE plasmid editor. The red bold sequence 
represents the sequence and the position of the primer used for DNA 
sequencing. 
3.3 Preparation of the linear plasmids for transfection 
According to the transfection technique reported by Ghorbal et al. (2014), the 
integrant parasites using a linear plasmid can be detected at the same time as 
for the circular plasmid. However, the advantage of using a linear plasmid is 
that the negative selection does not require the removal of the episomal 
parasites, which is a time-saving approach. In this study, three plasmids (pL7-
UMP-CMP kinase, pL7-DTC, pL7-KAHRP) were digested with the restriction 
enzyme HincII to produce the linear plasmids and the digested plasmids were 
then verified on agarose gel electrophoresis. The results showed that the 
linearization produced the expected bands but undigested plasmids were also 
found (Figure 3.15). Then, 10 µg of linear plasmid was used for co-transfection 
along with 60 µg of pUF1-Cas9 circular plasmid (plasmid size 11096 bp shown 




Figure 3.15 The circular and linearized plasmids for transfection 
For the co-transfection of pUF1-Cas9 plasmid and linear pL7-GOI plasmid, all 
plasmids after extraction and linearization by cutting with the restriction 
enzyme HinCII (double cutting in the yFCU cassette) were analysed on 0.8% 
agarose gel electrophoresis. Lane 1: pUF1-Cas9 circular plasmid (11096 bp), 
Lane 2: pL7-KAHRP circular plasmid, Lane 3: pL7-KAHRP linearized plasmid, 
Lane 4: pL7-UMP-CMP kinase circular plasmid, Lane 5: pL7-UMP-CMP 
kinase linearized plasmid (expected bands: 9168 bp and 747 bp), Lane 6: pL7-
DTC circular plasmid and Lane 7: pL7-DTC linearized plasmid (expected 
bands: 9241 bp and 747 bp). 
3.4 Generation of transgenic parasites 
In this study, four plasmids, pL7-UMP-CMP kinase, pL7-DTC, pL7-KAHRP, 
and pL7-KAHRP2 were used for establishing the CRISPR-Cas9 knockout 
system. The transfection experiment was performed in four individual 
transfection experiments. The first experiment was conducted for the co-
transfection of the pUF1-Cas9 plasmid and the linear plasmid of pL7-GOIs 
(UMP-CMP kinase and DTC) with the non-essential KAHRP gene (pL7-
KAHRP), obtained from the Pasteur Institute, as a positive control for the 
CRISPR-Cas9 system. The other three experiments were performed using the 
pUF1-Cas9 plasmid co-transfected with the circular plasmids of pL7-GOIs and 
used pL7-KAHRP2 (1.1 kb smaller than the pL7-KAHRP) as a positive control 
for the CRISPR-Cas9 system. In each transfection, 60 µg of pUF1-Cas9 and 
60 µg of pL7-GOI circular plasmid/10 µg of pL7-GOI linearized plasmid were 
mixed in the cytomix buffer and then the pelleted infected RBC with 8–10% 
parasitaemia at the early ring stage parasites was added, mixed gently, and 
then the electroporation was performed. After transfection, the parasites were 
cultured in 6 ml of complete RPMI medium (0.5% albumax) in 25 cm2 tissue 
culture flasks. Subsequently, 6 hours after transfection the inhibitors 1.5 nM 
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WR99210 and 300 µM DSM265 were applied to the culture flasks for selection 
of the parasites that only contained both plasmids. The drug pressure was 
applied for 5 days post-electroporation. The transfected parasites were then 
monitored by Giemsa-stained thin blood smear. On day 6 of post-transfection, 
no parasites were detected in the blood smears. The parasite cultures were 
continuously monitored for 60 days post-transfection and a routine blood 
smear was performed every week. From the thin blood smears analysis, after 
2 months of transfection, no viable parasites were detected from the transgenic 
parasites with the UMP-CMP kinase and DTC, whereas for the non-essential 
gene, KAHRP2, only a small number of ring parasites and unhealthy 
trophozoite parasites were observed on day 20 post-transfection (as depicted 
in Figure 3.16). Ring stage parasites are considered a reliable sign of a healthy 
parasite culture amongst malariologists. To rescue the unhealthy parasites, 
the complete RPMI medium, supplemented with 10% human serum, was used 
instead of albumax; however, the results showed the transgenic parasites 
failed to recover and there was no progress in the parasite development after 
2 months.  
 
 
Figure 3.16 Images of transgenic parasites of KAHRP2 
The viable parasites were detected from two batches of the transgenic 









3.5 Analysis of the transgenic parasites 
3.5.1 Primers for genotyping 
After the parasites were transfected with the two plasmids, the site-specific 
double strand DNA was broken by the Cas9 nuclease, and consequently, the 
cleaved target locus was repaired by homology recombination (using HR1 and 
HR2 flanking hdhfr), allowing hdhfr to be incorporated into the genome (Figure 
3.17 A). According to the four individual transfection experiments, the 
genotyping was performed for screening the integrant parasites after 7 days of 
transfection. In each experiment, genomic DNA was isolated from 3 ml of 
parasite cultures, then used for PCR analysis. Primers were designed to 
amplify the 5’ and 3’ integrations (the left and right homology arms) for 
evaluation of the donor DNA that was integrated into the target loci of each 
transgenic parasite as showed in Figure 3.17. Three sets of primers 
(KAHRP_GT_FW1/ GT_RV1, GT_FW2/ KAHRP_GT_RV2, and GT_FW2/ 
KAHRP_GT_RVb) were generated for evaluation of the KAHRP and KAHRP2 
mutant parasites. By using 5’ integration primers (KAHRP_GT_FW1/ 
GT_RV1) and the 3’ integration primers (GT_FW2/ KAHRP_GT_RV2), the 
expected size of the products of the KAHRP mutant were 1324 bp and 1043 
bp for 5’ integration and 3’ integration, respectively. The positions and 
directions of the primers, including the expected product sizes, are illustrated 
in Figure 3.17 B. The same primer sets for the KAHRP mutant were also used 
for evaluation of the KAHRP2 mutant but were used to amplify the different 
PCR products (as shown in Figure 3.17 C). The expected bands from the 
KAHRP2 mutant are 1205 bp and 380 bp for the 5’ integration and 3’ 
integration, respectively. In addition, a new set of primers (GT_FW2 and 
KAHRP_GT_RVb) was designed for assessment of the 3’ integration of the 
KAHRP2 mutant with a product size of 789 bp. It is a fact that the reverse 
primer of KAHRP_GT_RV2 is able to bind to the HR2 of the pL7-KAHRP2 
plasmid (except for the first 3 bases on the 5’ end). Ideally, the primer should 
not bind to any HR sequence to avoid any plasmid amplification. Therefore, a 
new reverse primer KAHRP_GT_RVb was created, allowing the primer to only 
bind to the genomic sequence. The schematic for the primer design is 
demonstrated in Figure 3.17 C.  
To evaluate the integrated parasites of the UMP-CMP kinase, 3 sets of primers 
were created with the positions, directions of the primers, and the expected 
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size of the PCR products as presented in Figure 3.17 D. Two sets of primers 
(UMP-CMP_GT_FW1/GT_RV1, and U3/ P1) were used for diagnostic PCR of 
the 5’ integration with products of 466 bp and 524 bp, respectively. Due to the 
AT-rich genomic sequence, the set of primers U3/P1 was designed to have a 
melting temperature at 59°C, while another set of primers (UMP-
CMP_GT_FW1/GT_RV1) was designed to have a melting temperature around 
54°C. It was reasoned that the higher melting temperature could provide 
greater specificity of target-binding. For the amplification of the 3’ integration 
of the mutant parasite, primers GT_FW2/UMP-CMP_GT_RV2 were used for 
diagnosis, generating a product size of 748 bp. 
In the assessment of DTC integrated parasites, the primer sets D3/P1 and 
P2/D4 were designed for verification of the 5’ and 3’ integration in the mutant 
parasite with the expected product sizes of 688 bp and 650 bp, respectively 
(Figure 3.17 E). These sets of primers were generated to have melting 
temperatures of 59°C. A summary of the primers and their sequences for 
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Figure 3.17 CRISPR-Cas9 system and an illustration of diagnostic 
primers used for genotyping  
(A) Schematic of the CRISPR-Cas9 system for gene disruption in P. 
falciparum. Two plasmids are required for transfection into the P. falciparum 
infected erythrocytes. The pL7-GOI contains sgRNA and the donor DNA 
template (hdhfr) is flanked with two homology regions for homology repair after 
a double- strand break. The site-specific double strand DNA is broken by the 
Cas9 protein, which is expressed from the plasmid pUF1-Cas9. The 
subsequent homology directed repair uses the sequence surrounding the 
cutting site from the donor DNA template, allowing the hdhr gene to integrate 
into the target locus. (B) Genotyping primers for verification of the integrant 
parasites of KAHRP (positive control taken from a published paper). (C) 
Genotyping primers for verification of the integrant parasites of KAHRP2. (D) 
Genotyping primers for verification of the integrant parasites of the UMP-CMP 
kinase. (E) Genotyping primers for verification of the integrant parasites of 
DTC. The outer primers are genomic DNA specific and the inner primers are 
hdhfr gene specific. The positions and directions of the primers are indicated 
by the small blue arrows and the expected size of the PCR products are 
presented between the blue arrows. 
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3.5.2 Genotyping   
Genomic DNA was isolated from the transgenic parasites of four individual 
transfection experiments and 10–20 ng of gDNA was then used for the analysis 
of gene disruption by genotyping. The first batch of transfections was the co-
transfection of the pUF1-Cas9 plasmid and the linear plasmid of pL7-GOIs 
(UMP-CMP kinase and DTC) with pL7-KAHRP as the control for the CRISPR-
Cas9 system. The PCR products from the genotyping were checked by 
agarose gel electrophoresis and were visualized under a UV transilluminator. 
As the results show in Figure 3.18, among 3 transgenic parasites, only 5’ and 
3’ integrations from the UMP-CMP kinase and 3’ integration from DTC were 
detected as PCR products with the expected sizes of 542 bp, 748 bp and 650 
bp, consecutively; however, non-specific bands were also observed from the 




Figure 3.18 Diagnostic PCR detection from the transfection experiment I  
For the first transfection experiment, the linear CRISPR plasmids were co-
transfected with pUF1 Cas9 plasmid. After 7 days of culturing, the parasite 
DNA was isolated and evaluated by genotyping, the PCR products were then 
analysed on 1.5% agarose gel electrophoresis. The primers were designed for 
detection of the integrated donor DNA template (hdhfr gene) in the 5’ and 3’ 
integrations from transgenic parasites and the expected size of each PCR 




For the second transfection experiment, co-transfection of the pUF1-Cas9 
plasmid and the circular plasmid of pL7-GOIs (UMP-CMP kinase and DTC) 
were performed, using pL7-KAHRP2 as a positive control for the CRISPR-
Cas9 system. In Figure 3.19, the integration of hdhfr in the target loci in 5’ and 
3’ integrations were detected as the expected bands (1205 bp and 380 bp) 
from the KAHRP2 transgenic parasites but non-specific bands were observed 
from the use of diagnostic primers for the 5’ integration (KAHRP_GT_FW1/ 
GT_RV1). Unexpectedly, the non-specific PCR products were also found in 
the wild-type genomic DNA sample. The DNA from the band with the expected 
size of 5’ integration in the genotyping test was subjected to Sanger 
sequencing to confirm successful integration (as the result was shown in 
Figure 3.22 A) whereas the 3’ integration it should be noted that the diagnostic 
primer of KAHRP_GT_RV2 for detection of the 3’ integration of KAHRP2 is 
able to bind to the HR2 of the pL7-KAHRP2 plasmid. Hence, the new set of 
primers (GT_FW2/ KAHRP_GT_RVb) as described in 3.5.1 Primers for 
genotyping will be used for diagnosis of the 3’ integration of KAHRP2 trangenic 
parasites. 
The diagnostic PCR of integrated mutant from UMP-CMP kinase clearly shows 
a PCR product of the expected size (748bp) was obtained for the 3’ 
integrations whereas the 5’ integrations showed a product size that was slightly 
higher than the expected size that might cause by the use of non-specific 
diagnostic primers (Figure 3.19). DNA sequencing was performed to confirm 
the incorporation of the hdhfr gene in the 3’ integration (the result showed in 
Figure 3.23 B). In addition, the unexpected result of PCR products were 
obtained from wild-type genomic DNA samples by using both pairs of the 
diagnostic primers. 
From the genotyping result of the DTC transgenic parasites, the incorporation 
of hdhfr in the 3’ integration was obtained as a PCR product with the expected 
size (650 bp) while the 5’ integration presented a negative genotyping result. 
Nevertheless, the positive genotyping of the integrated mutant in the 3’ 
integration from the DTC transgenic parasites was confirmed by Sanger 
sequencing as the result was depicted in Figure 3.24 B (the multiple sequence 
alignment was presented in the appendix, Figure A7 clone 3_DTC1 and clone 
3_DTC2). The 5’ integration of the DTC was not re-checked by diagnostic PCR 





Figure 3.19 Diagnostic PCR detection from the transfection experiment 
II 
For the second batch of transfection experiment, the circular CRISPR plasmids 
were co-transfected with pUF1 Cas9 plasmid. After 7 days of culturing, the 
parasite DNA was isolated and evaluated by genotyping, the PCR products 
were then analysed on 1.5% agarose gel electrophoresis. Genotyping was 
performed by using diagnostic primer that targeted integration of the hdhfr 
cassette in 5’ and 3’ integrations from the KAHRP2, UMP-CMP kinase and 
DTC transgenic parasites. The plasmid pL7-KAHRP2 was used as a positive 
control for the CRISPR system. The expected size of each PCR products is 
shown below the figure. 
 
Genotyping results from the third transfection experiment are depicted in 
Figure 3.20. Despite the presence of non-specific bands including in the wild-
type gDNA sample, the incorporation of the hdhfr gene in the 5’ integration and 
the 3’ integration for all transgenic parasites were detected at the expected 
sizes with the exception of the 5’ integration of the UMP-CMP kinase. The 5’ 
integration of the UMP-CMP kinase showed a PCR product that was larger 
than the expected size.  
Therefore, the diagnostic PCR was repeated by using a new set of primers 
(U3/P1) designed to have an annealing temperature of 59°C. These results 
showed a PCR product at the expected size 524 bp as shown in Figure 3.20 
B,  The incorporation of the hdhfr gene in the 5’ integration of the UMP-CMP 
kinase transgenic parasites was confirmed by DNA sequencing ( as the result 
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was demonstrated in Figure 3.23 A). It should be noted that the diagnostic 
primers for detection of the 3’ integration of KAHRP2 in this genotyping were 
GT_FW2/KAHRP_GT_RVb and generated a product size of 789 bp as 
expected size, then the integration was verified by Sanger sequencing as 
shown in Figure 3.22 B. For the transgenic parasites of DTC showed a positive 
genotyping result with 688 bp and 650 bp as expected bands for the 5’ 
integration and the 3’ integration, respectively. The positive genotyping 
products of DTC were confirmed the integration mutants by DNA sequencing 




Figure 3.20 Diagnostic PCR detection from the transfection experiment 
III 
For the third batch of transfection experiment, the circular CRISPR plasmids 
were co-transfected with pUF1 Cas9 plasmid. After 7 days of culturing, the 
parasite DNA was isolated and evaluated by genotyping, the PCR products 
were then analysed on 1.5% agarose gel electrophoresis.  (A) Genotyping was 
performed by using diagnostic primer that targeted integration of the hdhfr 
cassette in 5’ and 3’ integrations from the KAHRP2, UMP-CMP kinase and 
DTC transgenic parasites. The plasmid pL7-KAHRP2 was used as a positive 
control for the CRISPR system. (B) Re-diagnostic PCR product from 5’ 
integrations of UMP-CMP kinase. The expected sizes of genotyping are shown 




For the genotyping of the last transfection experiment, the results are 
illustrated in Figure 3.21. It can be seen that the targeted integration of the 
hdhfr cassette in the 5’ integration and 3’ integration for all transgenic parasites 
were detected at the expected sizes (as these positive genotyping results from 
the previous transfections were confirmed via DNA sequencing) although non-
specific binding of primers was observed.  
In summary, the genotyping results demonstrated a successful diagnostic 
PCR product. In addition, the obtained PCR products at the expected sizes 
were cloned into bacterial cells using the TOPO® TA cloning® kit or purified 
directly from the agarose gels and the samples were then subjected to Sanger 
sequencing to confirm the integration of the hdhfr gene in the target loci. 
 
 
Figure 3.21 Diagnostic PCR detection from the transfection experiment 
IV 
For the fourth batch of transfection experiment, the circular CRISPR plasmids 
were co-transfected with pUF1 Cas9 plasmid. After 7 days of culturing, the 
parasite DNA was isolated and evaluated by genotyping, the PCR products 
were then analysed on 1.5% agarose gel electrophoresis.  Genotyping was 
performed by using diagnostic primer that targeted integration of the hdhfr 
cassette in 5’ and 3’ integrations from the KAHRP2, UMP-CMP kinase and 
DTC transgenic parasites. The plasmid pL7-KAHRP2 was used as a positive 





3.5.3 Sequencing confirmed the successful integration of the hdhfr 
cassette into the target loci. 
The diagnostic PCR products, amplified from the gDNA of each transgenic 
parasite, were subjected to Sanger sequencing to confirm the incorporation of 
the hdhfr cassette in the 5’ and 3’ integration (left and right homology arms) at 
specific sites guided by sgRNA. The sequencing result of the obtained PCR 
products from the KAHRP2 transgenic parasites is illustrated in Figure 3.22. 
The diagnostic PCR product of the 5’ integration (referred to as clone 5’K13) 
shows the presence of the hdhfr cassette that was sequenced after the HR1 
(highlighted in the blue dashed box) as the predicted mutant sequence (Figure 
3.22 A). Moreover, 2 clones (3’ K4 and 3’ K6) obtained from the PCR analysis 
of the 3’ integration showed the sequence of the hdhfr cassette was inserted 
before the sequence of HR2 (as depicted in Figure 3.22 B). The DNA analysis 
by multiple sequence alignment of DNA sequencing compared with the wild-
type sequence and the predicted mutant sequence are shown in the appendix 
(Figure A2 and A3). 
For the verification of the integrated mutant UMP-CMP kinase and DTC, DNA 
sequencing confirmed successful integration of donor DNA into the targeted 
loci in the left and right homology arms as shown in Figure 3.23 and Figure 
3.24 for the UMP-CMP kinase and DTC, respectively. The sequence 
surrounding the homology region (between HR1 and HR2) presents the 
sequence of the hdhfr cassette as matched with the sequence of the predicted 
mutant. In addition, the DNA analysis by multiple sequence alignment 
confirmed the insertion of the hdhfr cassette into the targeted loci as shown in 















Figure 3.22 DNA sequencing confirms the hdhfr cassette was integrated 
into the target locus (KAHRP2) through use of the CRISPR-Cas9 system 
 The partial sequence of chromosome 2 from the wild-type P. falciparum strain 
3D7 was extracted from PlasmoDB as shown in the upper row. The predicted 
mutant sequence, generated by using APE plasmid editor, is shown in the 
lower row. (A) Sequencing result of the donor DNA (hdhfr) inserted into the left 
homology arm (5’ integration). (B) Sequencing results of 2 clones (3’K4 and 
3’K8) show the donor DNA (hdhfr) integrated into the right homology arm (3’ 
integration). The primers were designed to amplify each fragment represented 


















Figure 3.23 DNA sequencing confirms the hdhfr cassette was integrated 
into the target locus (UMP-CMP kinase) through use of the CRISPR-
Cas9 system 
The partial sequence of chromosome 1 from the wild-type P. falciparum strain 
3D7 was extracted from PlasmoDB shown in the upper row. The predicted 
mutant sequence, generated by using APE plasmid editor, is shown in the 
lower row. (A) Sequencing result of the donor DNA (hdhfr) that was inserted 
into the left homology arm (5’ integration). (B) Sequencing result of the donor 
DNA (hdhfr) was integrated into the right homology arm (3’ integration). The 


















Figure 3.24 DNA sequencing confirms the hdhfr cassette was integrated 
into the target locus (DTC) through use of the CRISPR-Cas9 system  
The partial sequence of chromosome 8 from the wild-type P. falciparum strain 
3D7 was extracted from PlasmoDB as shown in the upper row. The predicted 
mutant sequence, generated by using APE plasmid editor, is shown in the 
lower row. (A) Sequencing resultof the donor DNA (hdhfr) that was inserted 
into the left homology arm (5’ integration). (B) Sequencing results of 3 clones 
(3’D1, 3’D2 and 3’D3) show the donor DNA (hdhfr) that was integrated into the 
right homology arm (3’ integration). The primers were designed to amplify each 




Chapter 4 Discussion 
The main objective of this study was to utilise a CRISPR-Cas9 system to verify 
the essential biological functions of two potential drug targets in malaria 
parasites predicted by the metabolic model of Plasmodium falciparum. The 
set-up of a CRISPR-Cas9 system here could be applied for testing other 
predicted malaria drug targets. CRISPR-Cas9 gene editing of the human 
malaria parasite P. falciparum was first reported by Ghorbal et al. (2014). It is 
based on the co-transfection of two plasmids, one being the pUF1-Cas9 
plasmid that provides a Cas9 endonuclease for making the double strand 
break (DSB) in a site-specific of the target DNA, guided by sgRNA and another 
plasmid (pL7-GOI) that contains the sgRNA and the donor DNA template for 
homology recombination. This system demonstrated that the stably 
transfected parasites could be detected 8 days after transfection. Thus, the 
well-established CRISPR-Cas9 system in Plasmodium spp. provides a robust 
and high efficiency gene modification approach, that could bring about the 
application of basic biological research into new treatments and vaccine 
development against malaria.  
In this research, two genes, UMP-CMP kinase and dicarboxylate/ 
tricarboxylate carrier protein, were subjected to drug target validation via the 
CRISPR-Cas9 system. The original plasmid pL6 eGFP, obtained from Ghorbal 
et al. (2014), allows for genetic modification of other target loci in P. falciparum 
by changing the homology sequences and introducing new oligonucleotides of 
the targeted sgRNA into the plasmid. Construction of plasmids in this project 
started from the amplification of HR1 and HR2 of GOIs, then both fragments 
were cloned into the original plasmid via replacing the GFP 5' and GFP 3' with 
HR1 and HR2, respectively. The optimised PCR condition was achieved by 
using the PCR extension temperature at 62°C for all amplification of homology 
regions except the HR2 of UMP-CMP kinase. The optimal temperature for 
extension of that fragment was found to be 64°C. It has been reported that a 
reduction of the PCR extension temperature is required for the amplification of 
extremely A+T rich DNA, particularly in P. falciparum genomic DNA (Su et al. 
1996). This finding demonstrated that fragments with ~90% A+T rich content 
were successfully amplified by using the extension temperature at 60°C while 
a failure to achieve the correct PCR product occurred at 65°C and 72°C, 
suggesting that using low extension temperatures prevents the melting of the 
A+T rich DNA templates during the extension step. Therefore, the successful 
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amplification of homology regions in this study is very encouraging for re-
considering the optimized temperature for amplifying DNA fragments from P. 
falciparum genomic DNA. 
After obtaining the HR fragments, the insertion of those fragments into the 
plasmid pL6 eGFP was performed through the use of an In-Fusion cloning kit. 
In the beginning, the positive clones were screened by digestion with the 
restriction enzyme BclI since the restriction site of this enzyme was added into 
the forward primer, allowing for positive clone screening. The results showed 
a slightly shifted band after digestion, which was difficult to distinguish among 
the positive clones carrying the BclI restriction site and the backbone plasmid. 
It is important to note that the fragment sizes of the homology region are 
around 300–500 bp, not very different from the fragments of GFP 5' (341 bp) 
and GFP 3' (269 bp) where the homology regions were replaced. Thus, 
screening of the positive clones by enzyme digestion is not a proper technique 
for screening and this step was skipped for the further experiments.  
All clones were confirmed to have the correct sequence by Sanger 
sequencing. The introduction of annealed oligonucleotides of targeting sgRNA 
into the plasmid via replacement of the BtgZI adapter region (between the U6 
promoter and terminator) resulted in the seamless insertion of sgRNA, as 
confirmed by Sanger sequencing. It is important that the sgRNA has to insert 
into the corresponding site to ensure that the sgRNA was transcribed under 
U6 promoter. Then, the subsequent plasmid constructions of UMP-CMP 
kinase and DTC were used for the transfection into P. falciparum parasites. 
The transfection of the two circular plasmids into the parasites was performed 
by electroporation using 0.31 kV, 25 µF and 200 Ω resistance with 2 mm 
cuvettes on a BioRad Gene Pulser II and the synchronized ring-stage 
parasites (8–10% parasitaemia) were used for co-transfection. Similar to the 
previous successful transfection in P. falciparum, the intracellular ring-stage is 
the predominant stage of parasites used for routine transfection by 
electroporation because the ring parasites can be cultured in vitro and rapidly 
purified as a synchronous ring form. In addition, the ring-stage can tolerate the 
electroporation that causes damage to both the host cells and the parasites 
(Wu et al. 1995, Deitsch et al. 2001, Crabb et al. 2004). For the transfection 
method, electroporation is the only method that has been developed for 
introducing exogenous DNA into P. falciparum infected erythrocytes with 
consistent reliability and this method has been widely used. The transfection 
of plasmid DNA into the ring stage of P. falciparum using electroporation was 
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first successfully demonstrated by Wu et al. (1995). The conditions of 2.5 kV 
and 25 µF with 4 mm cuvettes was used for the routine electroporation. 
Consequently, in 1997, a new condition for electroporation by using 0.31 kV 
and 960 µF with 2 mm cuvettes showed more efficiency than the previous 
methods (Fidock and Wellems 1997). In this experiment, the conditions as 
described by Fidock, D.A., and Wellems, T.E (1997) were used for 
electroporation but boiled parasites (with burning) were observed after 
electroporation. Therefore, a modified condition with 0.31 kV, 25 µF and 200 
Ω resistance with 2 mm cuvettes was applied for all transfections of circular 
plasmids into the parasites. When comparing this with the previous conditions, 
using a high voltage/low capacitance electric pulse, presented by Wu et al. 
(1995) or a low voltage/high capacitance electric pulse from the protocol of 
Fidock, D.A., and Wellems, T.E (1997), both conditions were successful in 
transfecting ring-stage parasites P. falciparum, while the conditions used in 
this experiment involved a low voltage/low capacitance electric pulse. It is 
possible that the different conditions used here may have resulted in the low 
transfection efficiency because the results showed only a small number of 
parasites were detected among the non-essential (KAHRP2) transgenic 
parasites. Furthermore, the failure of recovery of the KAHRP2 transgenic 
parasites after 2 months may result from the highly inefficient transfection. 
Evaluation of the integrant parasites was performed by PCR analysis after 7 
days of transfection. As the genotyping results showed the repeatedly 
successful integrations of the donor DNA (hdhfr cassette) into the target locus 
of the transgenic parasites KAHRP2, UMP-CMP kinase and DTC while 
KAHRP, obtained for the Pasteur Institute showed a negative genotyping 
result (the experiment was repeated more than 4 times in our group). A 
possible reason for this is the vector length could contribute to transfection 
efficiency by electroporation. A previous study reported the transfection 
efficiency per moles of transfected DNA decreased in response to increasing 
vector length when DNA was transfected into HeLa cells by electroporation 
(Hornstein et al. 2016). Additionally, the entry of DNA into the nucleus by 
passive diffusion showed that the movement of the longer pieces of DNA is 
slower than for shorter pieces of DNA (Ludtke et al. 1999). Moreover, it should 
be highlighted that the two plasmids of the CRISPR-Cas9 system need to 
reach the parasite nucleus for gene modification, meaning that the plasmids 
have to pass through four membranes: the RBC membrane, the 
parasitophorous membrane, the parasite cytoplasm membrane and the 
parasite nucleus membrane. Hence, larger sized vectors might not end up in 
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the parasite nucleus after electroporation (Gopalakrishnan et al. 2013). When 
compared with the plasmid size used in this research, KAHRP (10971 bp), 
KAHRP2 (9818 bp), UMP-CMP kinase (9915 bp) and DTC (9999 bp) and 
among the four constructs, three of them (KAHRP2, UMP-CMP kinase and 
DTC) had a plasmid size smaller than 10 kb and showed the positive 
genotyping results and DNA sequencing confirmed successful integration of 
the mutant. Therefore, for further investigation of drug target validation in P. 
falciparum using the CRISPR-Cas9 system, the size of the plasmid should be 
taken into account. 
For the knockout UMP-CMP kinase and DTC using the CRISPR-Cas9 system, 
as established in this study it could be applied to other predicted malaria drug 
targets with an efficient and site-specific model for genome editing. The results 
as presented the hdhfr cassette was successfully incorporated into the target 
locus only 7 days post-transfection according to the integrated mutants that 
were detected by genotyping. By using diagnostic PCR primers, the presence 
of the PCR products from the wild-type genomic DNA was unexpected and 
presented the same bands with the expected sizes for the integrated mutants. 
The presence of unexpected bands in the wild-type sample could be caused 
by the contamination between the PCR reactions during preparation. In 
addition, non-specific binding of diagnostic primers was observed since 
various sizes of PCR products were obtained. In addition to this, optimization 
of the PCR conditions including preparation of PCR reactions carefully or 
designing new diagnostic primers may prove useful in genotyping.  
However, the PCR products obtained from genotyping with the expected sizes 
confirmed the insertion of the hdhfr cassette into the target loci by Sanger 
sequencing. The DNA sequences of the left and right homology arms showed 
the hdhfr cassette was correctly inserted into the cutting site of the target locus. 
These results indicate that the guide RNAs that were designed in this study 
can guide the Cas9 endonuclease to the site-specific target before the double-
strand DNA is cleaved by the endonuclease and the 300–500 bp of 
homologous templates were efficient in mediating the homology-directed 
recombination. 
During phenotype analysis, after drug selection the transgenic parasites were 
continuously monitored for 60 days post-transfection. Then, if there is an 
appearance of transgenic parasites, the negative selection (40 µm of 5-
Fluorocytosine) will be applied to select the parasites free of episomal mutants. 
Due to the presence of suicide gene yfcu (yeast cytosine deaminase and uridyl 
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phosphoribosyl transferase) in the plasmid pL7-GOI, 5-Fluorocytosine kills 
parasites that carry the transient plasmid. However, as transfectants were 
cultured for two months, episomes will not be maintained and are lost from the 
parasites during propagation in the absence of drug pressure (van Dijk et al. 
1997, O’Donnell et al. 2001). Thus, the negative selection is not required in 
this case.  
The failure of recovery of the non-essential KAHRP2 parasites could be 
explained by the transfection efficiency among P. falciparum being extremely 
low (~1 × 10-6) because the exogenous DNA has to traverse 4 membranes 
(O'Donnell et al. 2002). Some protocols presented that parasites were typically 
detected by Giemsa smear within 4-6 weeks (Wagner et al 2015). Moreover, 
according to the previous publication in “method in malaria research” 
recommends for growing the transfectants up to 75 days (Moll et al., 2008). 
Therefore, the appearance of transfectants in this study may also take longer 
than 2 months. Additionally, the conditions used for electroporation also affects 
the transfection efficiency as mentioned above. For the transgenic parasites 
of UMP-CMP kinase and DTC, no viable parasites were detected after 2 
months. In principle, for gene knockout by the CRISPR-Cas9 system, the 
successful integration of the hdhfr cassette into the target locus will result in 
the disruption of the gene function of the target. Hence there will be no parasite 
survivors if the GOI is an essential gene. The results from this study suggest 
that UMP-CMP kinase and DTC could have a crucial biological function for 
parasites.  
A recent publication used a different approach to identify essential genes 
throughout the genome. Zhang et al. (2018) used genome-wide saturation 
mutagenesis in P. falciparum using the piggyBac system. It is based on the 
AT-rich P. falciparum genome that allows for piggyBac transposons 
(integrating into sequences of TTAA) that can insert into targets, generating 
around 38,000 mutants with nonmutable (essential genes) and mutable 
(dispensable genes). UMP-CMP kinase and DTC were identified as essential 
genes in their study (Zhang et al. 2018). Thus, the findings in this project are 
consistent with this published data on non-viable parasites of both transgenes. 
In this study, however, the viability of each transgenic parasite needs to be 
further investigated using the quantitative approach via RT-qPCR to confirm 
the essentiality of UMP-CMP kinase and DTC. RT-qPCR is considered to be 
an effective approach for detection and quantification of mRNA transcripts of 
interest in complex environmental samples (Smith and Osborn 2009). Using 
such a technique may be able to confirm the living or dead parasites of 
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transgene UMP-CMP kinase and DTC by comparing them with the non-





























Chapter 5 Conclusions and recommendation 
In this research, two CRISPR plasmids (containing sgRNA and donor DNA for 
homology recombination) of pL7-UMP-CMP kinase and pL7-DTC were 
successfully constructed and co-transfected with the Cas9 plasmid into P. 
falciparum-infected erythrocytes. When the targeting gene was disrupted by 
the donor DNA (hdhfr) it allowed for investigation into its biological functions. 
Genotyping and DNA sequencing confirmed that the hdhfr cassette was 
integrated into the targeted locus, indicating the gene disruption of UMP-CMP 
kinase and DTC were successfully achieved through the CRISPR-Cas9 
system. For drug target evaluation, no visible viable parasites were detected 
for the transgenic parasites of UMP-CMP and DTC by Giemsa-stained thin 
blood smears. This result suggests that UMP-CMP kinase and DTC could be 
important for parasites survival. To confirm the essential function of both 
genes, quantitative RT-qPCR data is required and needs to be compared with 
a non-essential gene (KAHRP2). This information could validate both genes 
as therapeutic targets.  
For the non-essential transgenic parasites (KAHRP2), the genotyping result 
and DNA sequencing confirmed that the donor DNA was integrated into the 
KAHRP locus, allowing for gene disruption. The transgenic parasites were 
detected 20 days post-transfection and after that, there was no parasite 
development. This is contradictory to a previous study that reported that 
KAHRP gene disrupted parasites can be detected 8 days after transfection. In 
further investigation, the method for introducing DNA into the malaria parasites 
must be revised to improve the transfection efficiency. A previous study 
compared transfection efficiency of three electroporation techniques in P. 
falciparum. The transfection efficiency of the pre-loaded erythrocytes 
technique is about 180-fold higher than the direct electroporation of ring stage 
infected erythrocytes while the combined technique (using the direct 
electroporation of ring stage infected erythrocytes and parasites that were 
allowed to mature for 24 hours, then followed by the pre-loaded erythrocytes) 
was found to be 6-fold less efficient than the pre-loaded erythrocytes technique 
(Hasenkamp et al. 2012).  
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The pre-loaded erythrocytes technique transfers DNA into erythrocytes by 
electroporation prior to the parasites transfection by the invasion of DNA 
loaded erythrocytes. DNA is then taken up spontaneously from the host cell 
cytoplasm into the parasite’s nuclei (Deitsch et al. 2001). The advantage of 
this technique is that the parasites tend to be healthier because they are not 
electroporated, resulting in an improved viability rate. Moreover, the pre-
loaded erythrocytes technique has been successfully used in CRISPR-Cas9 
transfections with nearly 100 transfections (Ribeiro et al. 2018). Furthermore, 
human serum may help parasites recovery faster. A 20% pooled-human serum 
has been used for cloning transgenic parasites (Mogollon et al. 2016). 
Therefore, using a pre-loaded erythrocytes technique may maximize the 
transfection efficiency in P. falciparum and when applying the 20% human 
serum to the parasites culture, the transgenic parasites may be detected 
earlier.  
Another transfection technique that can improve the transfection efficiency in 
P. falciparum is plasmid-free CRISPR/Cas9 genome editing. This technique 
uses the recombinant Cas9 protein complex with synthetic guide RNAs 
(ribonucleoprotein, RNP) and single-stranded oligodeoxynucleotide (ssODN). 
This complex solution is then transfected into the synchronised ring-stage 
parasites. The introduction of the protein complex into the parasites is far 
easier than the use of circular plasmids. Based on the CRISPR-Cas9 system, 
the success of gene editing is subjected to the co-existence of two plasmids in 
the nucleus of parasites and the size of plasmids also has an effect on the 
transfection efficiency. Thus, a plasmid-free CRISPR/Cas9 genome editing 
system may lead to an improvement in the transfection of malaria parasites 
(Crawford et al. 2017).  
Finally, it has been recently reported that UMP-CMP kinase and DTC have 
been identified as essential genes in P. falciparum using the piggyBac system; 
however, there is a lack of biochemical data of a novel target of UMP-CMP 
kinase. Regarding DTC, although this protein has been purified and 
characterized, the available drug discovery and drug development information 
are still limited. Future investigation of both proteins should focus on their 
biochemistry, for example, recombinant protein production, enzyme 
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characterization, and crystallisation to understand their enzyme properties. 
This information can be used to guide rational-drug design and lead to 
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Table A1. Oligonucleotides used in this study 

































































Figure A2 Sequence alignment of KAHRP2 transgenic parasites at the 5’ 
integration compare with the predicted mutant sequence and the wild-type 










Figure A3 Sequence alignment of KAHRP2 transgenic parasites at the 3’ 
integration compare with the predicted mutant sequence and the wild-type 
















Figure A4 Sequence alignment of UMP-CMP kinase transgenic parasites at 
the 5’ integration compare with the predicted mutant sequence and the wild-
















Figure A5 Sequence alignment of UMP-CMP kinase transgenic parasites at 
the 3’ integration compare with the predicted mutant sequence and the wild-





Figure A6 Sequence alignment of DTC transgenic parasites at the 5’ 
integration compare with the predicted mutant sequence and the wild-type 








Figure A7 Sequence alignment of DTC transgenic parasites at the 3’ 
integration compare with the predicted mutant sequence and the wild-type 








Figure A8 DNA sequencing of homology region (HR1) of UMP-CMP kinase (clone. HR1_U2)           
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Signal: A (1763), C (934), G (865), T (2198)





Figure A9 DNA sequencing of homology region (HR1) of UMP-CMP kinase (clone. HR1_U3)    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N N A N N N NT C A T G A T T A C CA A A A G T T A T T T T T A A T A T T T T T T T T T A T G T T CA T A G T A A A A A A T C C A T A T T T G T T T G T C G A A A A T T T C T A C C T T T T A A A A A A T A G C A A G C A T T T T C C
130 140 150 160 170 180 190 200 210 220 230 240
T T T T T A C A T A A A T A G A A C T A A T G G T T C T T A T A A A A A G G A A C A A C C T T T T A A A A T T G A A A G C C A A C A T T A T A A T A A A A T A A C A A G A A A A T T T T A T A A A T T T A A G A A A A A T A T A T A C A C A T C
250 260 270 280 290 300 310 320 330 340 350 360
T A C A T C A A A C T T T T C T A T A A A C A G T T A T A A T A T T T G G G A A A A A C A A T T T T T A A G C A T T T T G T A A A A A A A A T T A A A A T A T A T T T A T A T A A T A T T A T T T T A T T T T A T T A T A T A T T A T A T T A T
370 380 390 400 410 420 430 440 450 460 470 480
T T T T A T T T T T A T T T T T A T T T T T T T T T C T C T A C A A A T T T T A T C T A T T G G T T T A T T A T A A A A A T A T C T A T T T C T A A T A A T A A A T A A T T A A G A T A T C A A T T T A T A G A A A C A A A A T A T A T A C T T
490 500 510 520 530 540 550 560 570 580 590 600
G T A T A A T T T T A T T T T T T T A T A T A A A T C A T T A C A T A T A T A A T T A T A C A A T A T T T T T T C T A A G A G A T A A T T A T A T A T T A A T A T A T A T A A A A A A A G G T G T T T T T T T T T T A T T T T T A T T T T T A T
610 620 630 640 650 660 670 680 690 700 710 720
T T T A T G G T A A T A T T T T A T T T T C C T T A T T G T A T A A A T T A T A T T A G T T T A T A T G T G A T T A A T T T T A T A T A T T A T C A A T T T A T A T A T T T T T A A A T G C T T A C T T A A T T A T C T T T T T T T T T A N T A
730 740 750 760 770 780 790




Signal: A (1075), C (498), G (424), T (1243)





 Figure A10 DNA sequencing of homology region (HR1) of UMP-CMP kinase (clone. HR1_U4)                    
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Signal: A (2788), C (1426), G (1207), T (3380)






 Figure A11 DNA sequencing of homology region (HR1) of UMP-CMP kinase (clone. HR1_U5)                    
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Signal: A (3079), C (1397), G (1397), T (4077)





Figure A12 DNA sequencing of homology region (HR2) of UMP-CMP kinase (clone. HR2_U9)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N T N G T N G A T A A T T C NT N T T A T T A T T T T T A C C G T T C CA T G T T A CA T A T T T G T A A A A A C A T A C T G A A T A T C A C T C CA A A C G T C T T G A A T A T T T T T A T T T G C A T T A A T A A A A A T G C A T T T
130 140 150 160 170 180 190 200 210 220 230 240
G T T T T C A T T T A A A A A T A A A T T T A T T A T A G G A A T A C A A T C A T T A T T A T G A G T A T C A A A T C G T T T T T T T A A T G T A T C C A T A T T A T C A T C T A C T C T T C C T A C A T A T A C A A A A A A T T A T A A A C A
250 260 270 280 290 300 310 320 330 340 350 360
C A C A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A T T A A A A T A T A T A A T T T T T T T T T T T T T T T T T T G T T T G T T T C G G A T T C A T T A A A T T C T T A C C A C A A G T T A A T C C T C T A T T C
370 380 390 400 410 420 430 440 450 460 470 480
A T A C A T C T C T C T A T C A T T A T C T C T T C A T C A C A A T A T A A A A A T A A A C A T A A A T G T A C A T A T G C A T A A T T T C C T A T T A T A T T A A T C C A T C C T G A T C A A A T T C T A G A T T T A A T A A A T A T G T T C
490 500 510 520 530 540 550 560 570 580 590 600
T T A T A T A T A A T G A G A A A T A A A T A T T T A A C A T A T G T T T A A A A A G A A A A A T T T A A G A T T T A C A T G A T T A G G A A T A A A A A T A T T A A A A G C T A T A T A T T A A T G T T G T A C T T T A T G T T C A T A T T G
610 620 630 640 650 660 670 680 690 700 710 720
T A A A A G A T A A A T A T A A T T T T T A T T A A A A T T T A T A T T T A T T A T T A T T A T A A G T T C T T A A A A A A T A C A T T T T G T T T T A A A A T A A T A C T A T A A A A A G A A C A A T A A T A A A A A T A A A A T A C A A T T
730 740 750 760 770 780 790 800 810 820 830 840
A A A A C A T A A T T A A A A A A G A A A A A T A C A G A C A G T A A A A A A A A T C G C T A T C C C A T A A A T T A C A A A A C A T G A A T T A A T A A A C A T A T A T T G C T T A T T A A T A A A A T T G T A A G T T A T T T T T A T A T A
850 860 870 880 890 900 910 920 930 940 950 960
T A C A T A A T A A A T T A A A G A T A C T G A A A C A A T A A T T T T A A A T G T A A A T A A A T G A A T A A T G A T A T G T T T T A T A T G A T T C A T T A T T C T A T A T T T A T A A G G A A G A T T A C A A A A A A A A A T T C A T A T
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
G T A T T T T T T T T G G A A T T C C G G G G T T A A G G T T T T A T T T T T A T A A T A T T T T T A A T C T A T T A T T A A A T A A G C T T A A T C A T T C T T C T C A T A T A C T T C A A A T T T G T A C T T A A T G C C T T T C T C C T C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
C T G G A C A T C A A A A A G A A C A C C T G G G T A T T C T G G C A G A A G T T T A A A T T T C T C C A A A T C A A T T T C T G G A A A A A A C G G G T C A C T T T C A A A G T C T T G C A T G A T C C T T G T C C C A A A A A A T T T A A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (1345), C (649), G (874), T (1619)





Figure A13 DNA sequencing of homology region (HR2) of UMP-CMP kinase (clone. HR2_U11)                    
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A A A T T C A T A T G T A T T T T T T T T G T A A T T C C G G G G T T A A G G T T T T A T T T T T A T A A T A T T T T T A A T C T A T T A T T A A A T A A G C T T A A T C A T T C T T C T C A T A T A C T T C A A A T T T G T A C T T A A T G C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
C T T T C T C C T C C T G G A C A T C A G A A A G A A C A C C T G G G T A T T C C G G C A A A A G T T T A T A T T T C T C C A A A T C A A T T T C T GG A A A A A A C G T G T C A C T T T C A A A G T C T T G C A T G A T C C T T G G C C C A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (1533), C (732), G (951), T (1818)





Figure A14 DNA sequencing of homology region (HR2) of UMP-CMP kinase (clone. HR2_U12)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N A A A A A T T A T T N N N A T A A T T C GT G T T A T T A T T T T T A C C G T T C CA T G T T A CA T A T T T G T A A A A A CA T A C T G A A T A T C A C T C CA A A C G T C T T G A A T A T T T T T A T T T G C A T T A A T A A A A
130 140 150 160 170 180 190 200 210 220 230 240
A T G C A T T T G T T T T C A T T T A A A A A T A A A T T T A T T A T A G G A A T A C A A T C A T T A T T A T G A G T A T C A A A T C G T T T T T T T A A T G T A T C C A T A T T A T C A T C T A C T C T T C C T A C A T A T A C A A A A A A T
250 260 270 280 290 300 310 320 330 340 350 360
T A T A A A C A C A C A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A T T A A A A T A T A T A A T T T T T T T T T T T T T T T T T G T T T G T T T C G G A T T C A T T A A A T T C T T A C C A C A A G T T A A T C C
370 380 390 400 410 420 430 440 450 460 470 480
T C T A T T C A T A C A T C T C T C T A T C A T T A T C T C T T C A T C A C A A T A T A A A A A T A A A C A T A A A T G T A C A T A T G C A T A A T T T C C T A T T A T A T T A A T C C A T C C T G A T C A A A T T C T A G A T T T A A T A A A
490 500 510 520 530 540 550 560 570 580 590 600
T A T G T T C T T A T A T A T A A T G A G A A A T A A A T A T T T A A C A T A T G T T T A A A A A G A A A A A T T T A A G A T T T A C A T G A T T A G G A A T A A A A A T A T T A A A A G C T A T A T A T T A A T G T T G T A C T T T A T G T T
610 620 630 640 650 660 670 680 690 700 710 720
C A T A T T G T A A A A G A T A A A T A T A A T T T T T A T T A A A A T T T A T A T T T A T T A T T A T T A T A A G T T C T T A A A A A A T A C A T T T T G T T T T A A A A T A A T A C T A T A A A A A G A A C A A T A A T A A A A A T A A A A
730 740 750 760 770 780 790 800 810 820 830 840
T A C A A T T A A A A C A T A A T T A A A A A A G A A A A A T A C A G A C A G T A A A A A A A A T C G C T A T C C C A T A A A T T A C A A A A C A T G A A T T A A T A A A C A T A T A T T G C T T A T T A A T A A A A T T G T A A G T T A T T T
850 860 870 880 890 900 910 920 930 940 950 960
T T A T A T A T A C A T A A T A A A T T A A A G A T A C T G A A A C A A T A A T T T T A A A T G T A A A T A A A T G A A T A A T G A T A T G T T T T A T A T G A T T C A T T A T T C T A T A T T T A T A A G G A A G A T T A C A A A A A A A A A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T T C A T A T G T A T T T T T T T T G T A A T T T C N GG G G T T A A G G T T T T T A T T T T T A T A A T A T T T T T A A T C T A T T A T T A A A T A A G C T T A A T C A T T C T T C T C A T A T A C T T C A A A T T T G T A C T T A A T G C C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
T T T C T C C T C C T G G A C A T C A G A A A G A A C A C C T G G G T A T T C C G GG C A G A A G T T T A A A T T T C T C C A A A T C A A T T T C T G G A A A A A A C G G G T C A C T T T C A A A G T C T T G C A T G A T C C T T G G C C C A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (1522), C (718), G (981), T (1751)





Figure A15 DNA sequencing of homology region (HR2) of UMP-CMP kinase (clone. HR2_U13)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N N N A A T T A T T N T N A T A A T T C G T G T T A T T A T T T T T A C C G T T C CA T G T T A CA T A T T T G T A A A A A C A T A C T G A A T A T C A C T C CA A A C G T C T T G A A T A T T T T T A T T T G C A T T A A T A A A A
130 140 150 160 170 180 190 200 210 220 230 240
A T G C A T T T G T T T T C A T T T A A A A A T A A A T T T A T T A T A G G A A T A C A A T C A T T A T T A T G A G T A T C A A A T C G T T T T T T T A A T G T A T C C A T A T T A T C A T C T A C T C T T C C T A C A T A T A C A A A A A A T
250 260 270 280 290 300 310 320 330 340 350 360
T A T A A A C A C A C A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A T T A A A A T A T A T A A T T T T T T T T T T T T T T T T T T G T T T G T T T C G G A T T C A T T A A A T T C T T A C C A C A A G T T A A T C
370 380 390 400 410 420 430 440 450 460 470 480
C T C T A T T C A T A C A T C T C T C T A T C A T T A T C T C T T C A T C A C A A T A T A A A A A T A A A C A T A A A T G T A C A T A T G C A T A A T T T C C T A T T A T A T T A A T C C A T C C T G A T C A A A T T C T A G A T T T A A T A A
490 500 510 520 530 540 550 560 570 580 590 600
A T A T G T T C T T A T A T A T A A T G A G A A A T A A A T A T T T A A C A T A T G T T T A A A A A G A A A A A T T T A A G A T T T A C A T G A T T A G G A A T A A A A A T A T T A A A A G C T A T A T A T T A A T G T T G T A C T T T A T G T
610 620 630 640 650 660 670 680 690 700 710 720
T C A T A T T G T A A A A G A T A A A T A T A A T T T T T A T T A A A A T T T A T A T T T A T T A T T A T T A T A A G T T C T T A A A A A A T A C A T T T T G T T T T A A A A T A A T A C T A T A A A A A G A A C A A T A A T A A A A A T A A A
730 740 750 760 770 780 790 800 810 820 830 840
A T A C A A T T A A A A C A T A A T T A A A A A A G A A A A A T A C A G A C A G T A A A A A A A A T C G C T A T C C C A T A A A T T A C A A A A C A T G A A T T A A T A A A C A T A T A T T G C T T A T T A A T A A A A T T G T A A G T T A T T
850 860 870 880 890 900 910 920 930 940 950 960
T T T A T A T A T A C A T A A T A A A T T A A A G A T A C T G A A A C A A T A A T T T T A A A T G T A A A T A A A T G A A T A A T G A T A T G T T T T A T A T G A T T C A T T A T T C T A T A T T T A T A A G G A A G A T T A C A A A A A A A A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
A T T C A T A T G T A T T T T T T T T G N A A T T C C G G G G T T A A G GT T T T T A T T T T T A T A A T A T T T T T A A T C T A T T A T T A A A T A A G C T T A A T C A T T C T T C T C A T A T A C T T C A A A T T T G T A C T T A A T G C C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
T T T C T C C T C C T G G A C A T C A G A A A G A A C A C C T G G G T A T T C T G G C A G A A A T T T A A A T T T C T C C A A A T C A A T T T C T G G A A A A A A C G T G T C C C T T T C A A A G T C T T G C A T G A T C C T T G G C C C A N A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (1661), C (806), G (1019), T (1843)






Figure A16 DNA sequencing of sgRNA of UMP-CMP kinase (clone. sgUMP2)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N N A T A C G G A C T A G C C T T A T T T T AA C T T G C T A T T T C T A G C T C T A A A A C C C A C A A A G G G T T G A T C T T T A C T C A A T A T T A T A T A C T T A A T A T G A A A T A T G T G C A T A T A G G A A A A A T T A
130 140 150 160 170 180 190 200 210 220 230 240
T G C A T T T T G G T T A C T C T A A T A T T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A A T A T A T T A T G T T A T A T A T A C A T A A C A T A T A C A T T T T T T A A T A A T A A T T T A C C C T T T A T T T T T A C A
250 260 270 280 290 300 310 320 330 340 350 360
T T A T A A A A A A T T A T A T T A C A G T A A A A A T A A A A G T T T A T T A T A T T A A T A G T T T T T T T T T T T T T T T T T T A A T T T A T G A A A T A T T T A A A T A T T T A A A A T T T T T T A A A T G A A T A A T T A T A T T T A
370 380 390 400 410 420 430 440 450 460 470 480
T A A T T A G A A A A A A A A A A A A A A A A A A A A A A A T A T A G C T T T T T A T A A A A T T T T T T T T T A T T T A T C A G A A C A A A C A A A A T T T T T T T T T T A T A T T A A A T T A A A A A A A T T T A T T A T T A T T T T A T G
490 500 510 520 530 540 550 560 570 580 590 600
T A T A T T T T T T T T T T T T T T C A T A A T A T A A A A A T A T T A T A T A T T T T G C C C T T T T T T A C A A T A T T T T T C A T A T A T A A A A G A A A A A A A A A A A A A A A A A A A A T A T T A T T G A A A A C C C T C A A G A T G
610 620 630 640 650 660 670 680 690 700 710 720
T G G A A A A A C C A A A A T G T C A A A A A A T T G T T C T A T T T A T A A A A A A G C C C C T T T T A A C A C A C A C A A A A A A A A A A A C G T G T A T G T A T A T A A A A C C C A C C A T T T T A A A A A T T T G C CT C C A A A A A T
730 740 750 760 770 780 790 800 810 820 830 840
A A T T G G A G C A C A C A C A C T A T G T G A C A T A A T A A C A A A A T A T T A C T T T A T C C C C G T A T A T T A T A A T A T C C CC C C C T T T T T T T T T T T T T T T T A A T T T A A A A A A A A T G T T T A A A A T T T T A A A A C
850 860 870 880 890 900 910 920 930 940 950 960
G T C T T T T A A A G T T T T A T T T A A A G G G A A A A A A A A A A A A A A A A A A A A A A A A A A G G A G G T T A T T T G A G G A A A T A A A T T G A G A A A A T A G G G G T A T T T AT T A A A A A A A C A C C CA A T A T T T T T A T A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
A A A A A G G C T G C C A T T A T T A A A T T A A G G G G T T T T T A A A A A A A A A A A A T A A A A A A A A A A T C T C C C C T C C T T T T T T A A A A G A G C A A T A A C C C C A A G G G G A A T A A T T T A T T T T A C C C C C C C T T A
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
A A A A A A A A A A A C C T T T T T T T G CGG G A T T G G G G G C T A A A C C C C T T T T A A A A A A A A A A A A A A A A A A A A A A A A A T T T T T T N TT T T T T T G A A A A A G G G T T T G C C C C T T T G G A A A A A A A T A T A A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300




Signal: A (965), C (290), G (256), T (879)






Figure A17 DNA sequencing of sgRNA of UMP-CMP kinase (clone. sgUMP4)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N NN G A T AA C G G A C T A G C C T T A T T T T AA C T T GC T A T T T C T A G C T C T A A A A C C C A C A A A G G G T T G A T C T T T A C T CA A T A T T A T A T A C T T A A T A T G A A A T A T G T G C A T A T A G G A A A A A T T
130 140 150 160 170 180 190 200 210 220 230 240
A T G C A T T T T G G T T A C T C T A A T A T T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A A T A T A T T A T G T T A T A T A T A C A T A A C A T A T A C A T T T T T T A A T A A T A A T T T A C C C T T T A T T T T T A C
250 260 270 280 290 300 310 320 330 340 350 360
A T T A T A A A A A A T T A T A T T A C A G T A A A A A T A A A A G T T T A T T A T A T T A A T A G T T T T T T T T T T T T T T T T T A A T T T A T G A A A T A T T T A A A T A T T T A A A A T T T T T T A A A T G A A T A A T T A T A T T T A
370 380 390 400 410 420 430 440 450 460 470 480
T A A T T A G A A A A A A A A A A A A A A A A A A A A A A T A T A G C T A T T T A T A T A A A T T T C T T T T A T T T A T C T G A A C A A G C A A G A A T T T T T T T T T A T A T T A A A T T A G A A T A A A T T A T T A T T A G T T T A T G T
490 500 510 520 530 540 550 560 570 580 590 600
A T A T A T T T T T T T T T T T T C A T A G T A T A T A A A T A T T A T A T A T A T T G T A C C T T T T T A C A A T A T A T T T C A T A T A T A G A A G A G A A A A A A A A A A A A A G A A G A T A T T A T T G T A A A A C C T C A A G A T G T
610 620 630 640 650 660 670 680 690 700 710 720
G T A G A A A T C C A A A T G T C A T G A A A T T G T T C T A T T T A T A T A A A A G T T C C T T T T A A T A C C C C C A A A A A A A A A A A C A T G T A T G T A T A T A A T A A C T A C C A A T T T A A T A A T T T G C A T C C A T A A A T A
730 740 750 760 770 780 790 800 810 820 830 840
A T T G T A G T A C A C A T A C T A T G T G A C A T A A T A A C A A A A T A T T A C T T T A T C T T C G T T T A T T T A A T T A T T T C G C C T T T T T T T T T T T T T T T T T A T T T A A A A A A T A T G T T T A A A A T T T A T A A C G T C
850 860 870 880 890 900 910 920 930 940 950 960
T T T T A A A G T T T A A T T A A G G G A A A A A A A A A A N A N N N N A N A A A A A A A A G G G A T T T A G G G A A G G A A T T A A G G A A A T A A G G G G A T T T T T T T A A A A A A A T T C C A A A A T T T A A A T A A A A A G A T G C C
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
A A T A A A A A A A A A A T G GC C T T T A A A A A A A A A AN T T A T T A A A A A A T T T C C C T A CC T T T T T A T A A A A G G T A A A T T C C C A A TG G T A A T T A A T T T A A T T C C C C T T T A A A A T A A A A C C T T T T T A A T
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
G G G T T T T G G G C T T A C C T C C T T T G A A A A A A A A A A A A A A A A A A A AA C T T N G C T T T C T T G G A A A G GG T T G C C C C T T T G A A A A A A A A T A A T T T A T T T T A C C T T T T G G G A A A A A A T T T T G G G G A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (1802), C (452), G (462), T (1615)





Figure A18 DNA sequencing of sgRNA of UMP-CMP kinase (clone. sgUMP4)                    
10 20 30 40 50 60 70 80 90 100 110 120
NN N N T N N N T AA C G G A C T A G C C T T A T T T T AA C T T G C T A T T T C T A G C T C T A A A A C C C A C A A A G G G T T G A T C T T T A C T C A A T A T T A T A T A C T T A A T A T G A A A T A T G T G C A T A T A G G A A A A A T T
130 140 150 160 170 180 190 200 210 220 230 240
A T G C A T T T T G G T T A C T C T A A T A T T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A A T A T A T T A T G T T A T A T A T A C A T A A C A T A T A C A T T T T T T A A T A A T A A T T T A C C C T T T A T T T T T A C
250 260 270 280 290 300 310 320 330 340 350 360
A T T A T A A A A A A T T A T A T T A C A G T A A A A A T A A A A G T T T A T T A T A T T A A T A G T T T T T T T T T T T T T T T T T T T A A T T T A T G A A A T A T T T A A A T A T T T A A A A T T T T T T A A A T G A A T A A T T A T A T T
370 380 390 400 410 420 430 440 450 460 470 480
T A T A A T T A G A A A A A A A A A A A A A A A A A A A A A A T A T A G C T A T T T A T A T A A A T T T C T T T T A T T T A T C T G A A C A A G C A A A A A T T T T T T T T T A T A T T A A A T T A A A A T A A A T T A T T A T T A G T T T A T
490 500 510 520 530 540 550 560 570 580 590 600
G T A T A T A T T T T T T T T T T T T C A T A G T A T A T A A A T A T T A T A T A T A T T G A C C C T T T T T A C A A T A T A T T T C A T A T A T A G A A G A G A A A A A A A A A A A A A A A A A A T A T T A T T G T A A A A C C C C A A G A T
610 620 630 640 650 660 670 680 690 700 710 720
G T G T A A A A A T C C A A A T G T C A G G A A A T T G T C C T A T T T A T A A A A A A G T C C C T T T T A A T C C C C C C A A A A A A A A A A A C A T G T T T G T A T A T A A A A A C T A C C A A T T T A A T A A T T T G C A C C C A T A A A
730 740 750 760 770 780 790 800 810 820 830 840
T A A T T G T G G T A CA C A T A C T A T G T G A C A T A A T A A C A A A T A T T A C T T T A C C T C C G T T A A T T T A A T A A T T C C G C C T T T T T T T T T T T T T T T T T T AT T T A A A A A N A T G T T T A A A A T T T N A A C G T C
850 860 870 880 890 900 910 920 930 940 950 960
T T TT A A A G T T T A T T T A A G G G A A A A A A A A A A A A A A A A A A A A A A A A G G G A T T T A G G A G N A A T A A G A A A T A A G G G A T N T T T A A A A A TA T C C A A A A T T A A A T A A A A G A G G C A A T A T A A T A A A T G
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
G C T T T N A A A A A A A T T T A T A A A A T A T C C C A C C T T T T T A A A A G G T A A T T C C C A T G G G A A T T T A T T T T A T C C C C T T T A A A A A A A A C C T T T T N A T G G G T T T G G G C T T A C C A C C T T A A A A A A A A A
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
C A A A A A A A A A A A T T T C C T T TC T G G A A C G G T G G C C C T T G G A A A A A A A T T A A T A T T T A A C A T T G G G A A A A T T T G G G G A A A T T C CG G T T A A T T T T T A CG G T T C C G G T T C A A T T T G G A A A A A A T
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300




Signal: A (1187), C (339), G (277), T (1077)





Figure A19 DNA sequencing of homology region (HR1) of DTC (clone. HR1_DTC3)                    
 
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N A T N G A CA G A G AT A T A G C T A A A T A T G A T T T A G A A T CA A G T T CA A N N NT T G A T G T T A A T A A A A A G G G G A A T A A T A A C A A G A G T G T T T T T G A A A A G A T A A A A C C A T T C G C A G T A G G A
130 140 150 160 170 180 190 200 210 220 230 240
G G A G C A A G T G G T A T G T T T G C C A C A T T T T G T A T C C A A C C A T T A G A T A T G G T A A A A G T A A G A A T T C A A T T A A A T G C T G A A G G A A A A A A T G T A T T A A G G A A T C C A T T T A T A G T T G C T A A G G A C
250 260 270 280 290 300 310 320 330 340 350 360
A T A A T A A A G A A T G A A G G A T T T T T G T C A T T A T A T A A A G G A T T A G A T G C T G G A T T A A C T C G T C A A G T T A T T T A T A C T A C T G G T C G A T T A G G A T T A T T T C G T A C T T T T T C A G A C A T G G T A A A A
370 380 390 400 410 420 430 440 450 460 470 480
A A A G A A G G A G A A C T T A A G C A T T T T G T A A A A A A A A T T A A A A T A T A T T T A T A T A A T A T T A T T T T A T T T T A T T A T A T A T T A T A T T A T T T T T A T T T T T A T T T T T A T T T T T T T T T C T C T A C A A A T
490 500 510 520 530 540 550 560 570 580 590 600
T T T A T C T A T T G G T T T A T T A T A A A A A T A T C T A T T T C T A A T A A T A A A T A A T T A A G A T A T C A A T T T A T A G A A A C A A A A T A T A T A C T T G T A T A A T T T T A T T T T T T T A T A T A A A T C A T T A C A T A T
610 620 630 640 650 660 670 680 690 700 710 720
A T A A T T A T A C A A T A T T T T T T C T A A G A G A T A A T T A T A T A T T A A T A T A T A T A A A A A A A G G T G T T T T T T T T T T A T T T T T A T T T T T A T T T T A T G G T A A T A T T T T A T T T T C C T T A T T G T A T A A A T
730 740 750 760 770 780 790 800 810 820 830 840
T A T A T T A G T T T A T A T G T G A T T A A T T T T A T A T A T T A T C A A T T T A T A T A T T T T T A A A T G C T T A C T T A A T T A T C T T T T T T T T T T T T T T N N T T T T T T T C C A T C C T T T T A A A T T A A A T T A A A T T T
850 860 870 880 890 900 910 920 930 940 950 960
T G A A A A A A T T G A A A T T A A T T A T A TA T A T T A A A TA T A A T A T A T A T A C A GG T A G G A G T A T T A AC A C C G G G A T A C A G A C T A G A A GA AG A A A T T T A CA A A T T G C C T T C C A A T T T A A A T TG A A CG
970 980 990 1000 1010




Signal: A (4758), C (1549), G (3933), T (4981)





Figure A20 DNA sequencing of homology region (HR1) of DTC (clone. HR1_DTC4)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N NN N N A T G G A CA G A G AT A T A G C T A A A T A T G A T T T A G A A T CA A G T T CA A N T N T T G A T G T T A A T A A A A A G G G G A A T A A T A A C A A G A G T G T T T T T G A A A A G A T A A A A C C A T T C G C A G T A G G A
130 140 150 160 170 180 190 200 210 220 230 240
G G A G C A A G T G G T A T G T T T G C C A C A T T T T G T A T C C A A C C A T T A G A T A T G G T A A A A G T A A G A A T T C A A T T A A A T G C T G A A G G A A A A A A T G T A T T A A G G A A T C C A T T T A T A G T T G C T A A G G A C
250 260 270 280 290 300 310 320 330 340 350 360
A T A A T A A A G A A T G A A G G A T T T T T G T C A T T A T A T A A A G G A T T A G A T G C T G G A T T A A C T C G T C A A G T T A T T T A T A C T A C T G G T C G A T T A G G A T T A T T T C G T A C T T T T T C A G A C A T G G T A A A A
370 380 390 400 410 420 430 440 450 460 470 480
A A A G A A G G A G A A C T T A A G C A T T T T G T A A A A A A A A T T A A A A T A T A T T T A T A T A A T A T T A T T T T A T T T T A T T A T A T A T T A T A T T A T T T T T A T T T T T A T T T T T A T T T T T T T T T C T C T A C A A A T
490 500 510 520 530 540 550 560 570 580 590 600
T T T A T C T A T T G G T T T A T T A T A A A A A T A T C T A T T T C T A A T A A T A A A T A A T T A A G A T A T C A A T T T A T A G A A A C A A A A T A T A T A C T T G T A T A A T T T T A T T T T T T T A T A T A A A T C A T T A C A T A T
610 620 630 640 650 660 670 680 690 700 710 720
A T A A T T A T A C A A T A T T T T T T C T A A G A G A T A A T T A T A T A T T A A T A T A T A T A A A A A A A G G T G T T T T T T T T T T A T T T T T A T T T T T A T T T T A T G G T A A T A T T T T A T T T T C C T T A T T G T A T A A A T
730 740 750 760 770 780 790 800 810 820 830 840
T A T A T T A G T T T A T A T G T G A T T A A T T T T A T A T A T T A T C A A T T T A T A T A T T T T T A A A T G C T T A C T T A A T T A T C T T T T T T T T T T T T N T N NT T T T T T T C C C T C C T T T T A A A A T T T A T T T A A T T T
850 860 870 880 890 900 910 920 930 940 950 960
T T G A A A A A A T T G A T A T A T N T A T A T A T A T A T A T A A T A T A T A T A A A T A T A C A T G T A T A A T C T T T A A A C A A T G T A T A A T A T A C A A A A A T A A A A A A T T T A T A A A T A C CA T T C C A A A T T A A A A T T
970 980 990 1000 1010 1020




Signal: A (4252), C (1380), G (3718), T (3763)





Figure A21 DNA sequencing of homology region (HR2) of DTC (clone. HR2_DTC7)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N N N T A N T A T G T G A A AT T A T T G T G AT A A T T C G T G T T A T T A T T T T T A C C G T T C CA T G T T G A A T A G A A C A A T C T A A C A T A T T T T T A T A G G GC A T T T T C T T A G T A A C A G G AT C T GC T T T
130 140 150 160 170 180 190 200 210 220 230 240
C A T T T T T T G C A T G C A A G T T T T A A C A A A A T C A A A A G G T A A A C T T A A A G T G A C C G C A A A A A A G C C A C T A A T A A C A C T A G C A A C C A G A T T A G T C T T C A T A C C A A C A C C A A G A T A T T T T T G T A A
250 260 270 280 290 300 310 320 330 340 350 360
A A A T T C T T T T G A T T G A T C A T A A G T A G A A A G C A T T C C T A A A T T T A A T G A C A T G G C T C T A G C T A T A G T T G G A A C C G A A C C T T T C C A T A A A G C A A A T A A T C C T T C T T C T T T T G A A A T T C T A T A
370 380 390 400 410 420 430 440 450 460 470 480
T A A T G C A T T A A A C A C A C C A G T A T A A T T C C T T T T T A A T T C T T T T G G T A A T G T A T T A T C A G C T T G T A A T C T A A T T A A A G A T A A A T C T G C A G G T G A T C A A A T T C T A G A T T T A A T A A A T A T G T T
490 500 510 520 530 540 550 560 570 580 590 600
C T T A T A T A T A A T G A G A A A T A A A T A T T T A A C A T A T G T T T A A A A A G A A A A A T T T A A G A T T T A C A T G A T T A G G A A T A A A A A T A T T A A A A G C T A T A T A T T A A T G T T G T A C T T T A T G T T C A T A T T
610 620 630 640 650 660 670 680 690 700 710 720
G T A A A A G A T A A A T A T A A T T T T T A T T A A A A T T T A T A T T T A T T A T T A T T A T A A G T T C T T A G A A A A T A C A T T T T G T T T T A A A A T A A T A C T A T A A A A A G A A C A A T A A T A A A A A T A A A A T A C A A T
730 740 750 760 770 780 790 800 810 820 830 840
T A A A A C A T A A T T A A A A A A G A A A A A T A C A G A C A G T A A A A A A A A T C G C T A T C C C A T A A A T T A C A A A A C A T G A A T T A A T A A A C A T A T A T T G C T T A T T A A T A A A A T T G T A A G T T A T T T T T A T A T
850 860 870 880 890 900 910 920 930 940 950 960
A T A C A T A A T A A A T T A A A G A T A C T G A A A C A A T A A T T T T A A A T G T A A A T A A A T G A A T A A T G A T A T G T T T T A T A T G A T T C A T T A T T C T A T A T T T A T A A G G A A G A T T A C A A A A A A A A A T T C A T A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T G T A T T T T T T T T G N A A T T T C T G G G T T T A G G T T T T T A T T T T T A T A A T A T T T T T A A T C T A T T A T T A A A T A A G C T T A A T C A T T C T T C T C A T A T A C T T C A A A T T T G T A C T T A A T G C C T T T C T C C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
T C C T G G A C A T C A G A G A G A A C A C C T G G G T A T T C T G G C A G A A G T T T A T A T T T C T C C A A A T C A A T T T C T G G A A A A A A C G T G T C A C T T T C A A A G T C T T G C A T G A T C C T T G T C A C A A A T A G T T T A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (2933), C (1403), G (1469), T (3112)





Figure A22 DNA sequencing of sgRNA of DTC (clone. sgDTC7)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N T T NT A G TT G AT AA C G G AC T A G C C T T A T T T T AA C T T G C T A T T T C T A G C T C T A A A A C C CA A T A A A G GC T C C T A A T C C A C C A A T A T T A T A T A C T T A A T A T G A A A T A T G T G C A T A T A G
130 140 150 160 170 180 190 200 210 220 230 240
G A A A A A T T A T G C A T T T T G G T T A C T C T A A T A T T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A A T A T A T T A T G T T A T A T A T A C A T A A C A T A T A C A T T T T T T A A T A A T A A T T T A C C C T T T
250 260 270 280 290 300 310 320 330 340 350 360
A T T T T T A C A T T A T A A A A A A T T A T A T T A C A G T A A A A A T A A A A G T T T A T T A T A T T A A T A G T T T T T T T T T T T T T T T T T T A A T T T A T G A A A T A T T T A A A T A T T T A A A A T T T T T T A A A T G A A T A A
370 380 390 400 410 420 430 440 450 460 470 480
T T A T A T T T A T A A T T A G A A A A A A A A A A A A A A A A A A A A A A A A A T A T A G C T A T T T A T A T A A A T T T C T T T T A T T T A T C T G A A C A A G C A A A A A T T T T T T T T N A T A T T A A A T T A G A A T A A A T T A T T
490 500 510 520 530 540 550 560 570 580 590 600
A T T A G T T T A T G T A T A T A T T T T T T T T T T T N C A T A G T A T A A A A A T A T T A T A T A T A T T G N N C C T T T T T A C A A T A T A T T T C A A A T A T A G A A A A A A A A A A A A A A A A A A G A A A A T T T T A T T G A A A A
610 620 630 640 650 660 670 680 690 700 710 720
A C C C C A A A A T G T G T A A A A A C C C A A A T G T C A T G A A A T T G T T C T A T T T A A N A A A A A G T T C C T T T T A A T A C C C A C A A A A A A A A A A A C A T G T A T G T A T A T A A A A A C T A C C A A T T T A A T A A T T T G
730 740 750 760 770 780 790 800 810 820 830 840
C NN C C A T A A A T A A T T G T A G T A C A C A T A C T A T G T G A C A T A N N A C C A A A A T A T T A C T T T A T C T C C G T T A A T T T A A T A A T T C C G C C T T T T T T T T T T T T T T T A A T T T A A A A A A T A G G T T T A A A A
850 860 870 880 890 900 910 920 930 940 950 960
T T T A A A A C G T C T T T T A A A G T T T A T T T A A G G G A A A A A A A A A A A A A A A A C A A A A A G G G A T T T T G G G A G G A A T T A G G A A N N A A G G G A T T T T T T A A A A A A N T C C C A A A T T T A N N A A A A A N N T G C
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
C A T A A T A A A A A A N T G G C T T T A A A A A A A A A A A N NN T T A A A A A T T T C C C T C C T T T T T A A A A A G G A A A A T T C C N NN G G G A A T T T T T T T T T A T C C C C T T A A AA A A A A N C C T T T T N N T G G G G T T T
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
T G G C C T A A C N NCC T T G A A A A A A A A C C A A A A T A A A AC C T T T G C T T T C TT G A A A CG G G G G G C C C T T G G A A A A A A A A A A A A A A A A A N C C A A T G G G A A A A A A T T T T G G G A A A T T C C G G G T T A A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (933), C (277), G (220), T (921)





   Figure A23 DNA sequencing of sgRNA of DTC (clone. sgDTC8)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N TN N A T A C G G A C T A G C C T T A T T T T AA C T T G C T A T T T C T A G C T C T A A A A C C CA A T A A A G GC T C C T A A T C CA C C A A T A T T A T A T A C T T A A T A T G A A A T A T G T G C A T A T A G G A A A A A T T A
130 140 150 160 170 180 190 200 210 220 230 240
T G C A T T T T G G T T A C T C T A A T A T T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A A T A T A T T A T G T T A T A T A T A C A T A A C A T A T A C A T T T T T T A A T A A T A A T T T A C C C T T T A T T T T T A C A
250 260 270 280 290 300 310 320 330 340 350 360
T T A T A A A A A A T T A T A T T A C A G T A A A A A T A A A A G T T T A T T A T A T T A A T A G T T T T T T T T T T T T T T T T T A A T T T A T G A A A T A T T T A A A T A T T T A A A A T T T T T T A A A T G A A T A A T T A T A T T T A T
370 380 390 400 410 420 430 440 450 460 470 480
A A T T A G A A A A A A A A A A A A A A A A A A A A A A A A A T A T A G C T A T T T A T A T A A A T T T C T T T T A T T T A T C T G A A C A A G C A A G A A T T T T T T T T T A T A T T A A A T T A G A A T A A A T T A T T A T T A G T T T A T
490 500 510 520 530 540 550 560 570 580 590 600
G T A T A T A T T T T T T T T T T T T C A T A G T A T A T A A A T A T T A T A T A T A T T G N N C C T T T T T A C A A T A T A T T T C A T A T A T A G A A G A G A A A A A A A A A A A A N G A N N A T T T T A T T G T A A A A C C C C A A G A T
610 620 630 640 650 660 670 680 690 700 710 720
G N G T A G A A A T C C A A A T G T C A G G A A A T T G T T C A A T T T A N A A A A A A G T T C C T T T T A A T A C C C C C A A A A A A A A A A A C A T G T A T G T A T A T A A T A A C T A C C A A T T T A A T A A T T T G C A T C C A T A A A
730 740 750 760 770 780 790 800 810 820 830 840
T A A T T G T A G T A C A C A T A C T A T G T G A C A T A A T A A C A A A A T A T T A C T T T A T C T T C G T T T A T T T T A T T A T T C C G C C T T T T T T T T T T T T T T T T T T T N A A A A A A A N G G T T T A A A A T T T A A A A C G C
850 860 870 880 890 900 910 920 930 940 950 960
C T T T T A A A G T T T A T T T A A G G G A A A A A A A A A A A A A T T T T A TT A A T A G G G AT T T T G G G G G G A A A T T A A G A A A A T A G G G G T T T T T T T A A A A A A N C C C A A A T T T T A A A A A A N G G GN N C C A A A A A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
A A A A A A G G G C T T T T A A A A A A A A A T T T T T A A A A A A T T CC C C C CC T T T T T A A A A A G G A A A A T C C C A G G G G G A T T T T A T T T T A A T C C C C T T T A A A A A A A A N C C T T T T T AA G G G G G T T T G G GG C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
T T A C C C C C T T T A A A A A A A A A N C A A A A A A A A A A N T T T G T T T T T N G G A A C G G G T G C C C C T T N G A A A A A N T A A A N T T A T T N N CC C A T T G G G G A A A A A A T T T GG G G G A A A T TCC G G G G T T A A T T
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (1533), C (488), G (425), T (1473)




      
Figure A24 DNA sequencing from genotyping of 5’ integration of KAHRP2 transgenic parasites (clone. 5’ K13)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N N T TT T T TA T N N N A A NA AT A T T NN N N N N NAN NN NN N N NN N N N AN N N NN NN NN NN NN N T A T A T A T A T A T A T G T G NN N T T T A A A A A A T A T G A A A T A T A T A T T T A T A T A T T A T T A T T T T
130 140 150 160 170 180 190 200 210 220 230 240
C T T A T T T T A T T T T T A T T T T A T T T T A T T T T A T T T T A A T T T T A T T T T A T T T T A T T T T A A T T T T A T T T T A A T T T T A T T T T A A T T T T A T T T T A A T T T T A T T T T A A T T T T A T T T T A T T T T A A T T T
250 260 270 280 290 300 310 320 330 340 350 360
T A T T T T A T T T T A T T T T A A T T T T A T T T T A T T T T A T T T T A A T T T T A T T T T A T T T T A T T T T A A T T T A A T T T T A T T T T T T T T T T C A T A T A G T G C A A T A A T G G A A A C G G A T C C G G T G A C T C C T T C
370 380 390 400 410 420 430 440 450 460 470 480
G A T T T C A G A A A T A A G A G A A C T T T A G C A C A A A A G C A A C A T G A A C A C C A T C A C C A C C A T C A C C A T C A A C A T C A A C A C C A A C A C C A A G C T C C A C A C C A A G C A C A C C A C C A T C A T C A T C A T G G A
490 500 510 520 530 540 550 560 570 580 590 600
G A A G T A A A T C A C C A A G C A C C A C A G G T T C A C C A A C A A G T A C A T G G T C A A G A C C A A G C A C A C C A T C A C C A T C A T C A C C A C C A T C A T C A A T T A C A A C C T C A A C A A C C C C A G G G A A C A G T T G C T
610 620 630 640 650 660 670 680 690 700 710 720
A A T C C T C C T A G T A A T G A A C C A G T T G T A A A A A C C C A A G T A T T C A G G G A A G C A A G A C C A G G T G G A G G T T T C A A A G C A T A T G A A G A A A A A T A C G A A T C A A A A C A C T A T A A A T T A A A G G A A A A T
730 740 750 760 770 780 790 800 810 820 830 840
G T T G T C G A T G G T A A A A A A G A T T G T G A T G A A A A A T A C G A A G C T G C C A A T T A T G C T T T C T C C G A A G A G T G C C C A T A C A C C G T A A A C G A T T A T A G C C A A G A A A A T G G T C C A A A T A T A T T T G C C
850 860 870 880 890 900 910 920 930 940 950 960
T T A A G A A A A A G A T T C C C T C T T G G A A T G A A T G A T G A A G A T G A A G A A G G T A A A G A A G C A T T A G C A A T A A A A G A T A A A T T A C C A G G T G G T T T A G A T G A A T A C C A A A A C C A A T T A T A T G G A A T A
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T G T A A T G A G A C A T G T A C C A C A T G T G G A C C T G C C G C T A T A G A T T A T G T T C C A G C A G A T G C A C C A A A T G G C T A T G C T T A T G G A G G A A G T G C A C A C G A T G G T T C T C A C G G T A A T T T A A G A G G A
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
C CN G A T A A T A A A G G T T T T A A G C A T T T T G T A A A A A A A T T A A A T A A N T T T A N N T A A A A T T A T T T T A T T T T A T T A A A A A T A A A A T A A T T T T A T T T T A A A T T T T A T T T T T T T T T C C C C N C A A A T
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (5694), C (2319), G (1570), T (6569)





    Figure A25 DNA sequencing from genotyping of 3’ integration of KAHRP2 transgenic parasites (clone. 3’ K4)                    
10 20 30 40 50 60 70 80 90 100 110 120
N N N NN NN A N N AA T C G C C T TTA N N N N N N N A C A T TNN A TTA TTA T A G C T T T T A A T A T T T T T A T T C C T A A T CA T G T A A A T C T T A A A T T T T T C T T T T T A A A C A T A T G T T A A A T A T T T A T T T C T C
130 140 150 160 170 180 190 200 210 220 230 240
A T T A T A T A T A A G A A C A T A T T T A T T A A A T C T A G A A T T A G C A A G T A C T T C T A A A G G A G C A A C T A A A G A A G C A A G T A C T A C T G A A G G A G C A A C T A A A G G A G C A A G T A C T A C T G C A G G T T C A A C
250 260 270 280 290 300 310 320 330 340 350 360
T A C A G G A G C A A C T A C A G G A G C T A A T G C A G T A C A A T C T A A A G A T G A A A C T G C C G A T A A A A A T G C T G C A A A T A A T G G T G A A C A A G T A A T G T C A A G A G G A C A A G C A C A A T T A C A A G A A G C A G G
370 380 390 400 410 420 430 440 450 460 470 480
A A A G A A A A A G A A G A A A A G A G G A T G C T G T G G T T A A A T A A T C T C T G C A G T T G A T T C A T A A A A T A T A A T T A C T T T T T G A A T T A G A A A G A T A T A C C A A T A A A T A T A T A T T T T T T T A A A A T A T A C
490 500 510 520 530 540 550 560 570 580 590 600
T T C G A A G G T A T A G A T A A T A T A T T A T A T G A A T A G A G A A A A T C A A A T A A A A T C T T A A T A T A A A A A A G A A A C A T T A A T A T A A A T G A A A A T T A T A T T G A A A G A A T G T A G A A T A A A A A T A T G T T A
610 620 630 640 650 660 670 680 690 700 710 720
A T T A A A T A T A A G A T T T T G A T T A C A A T C A T T T T A A C A T A T T T T A T T T T T T T T T A T T A A G A C G T A T T T A A G C A T A A A T A T A A G G A A A A C A A G T A T A T G C A T A T A T A T A T A T A T A T A T A T A T A
730 740 750 760 770 780 790 800 810 820 830 840
T A T A T T A T G T G T A T A A A A T T A T A A T T A T A A A T A A A A T T A G G A T T T T A A A G A T A A T T A A A T T T A A T T T G A C G T T T A T A C A G A A A A G A G T A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C
850 860 870 880 890 900 910 920 930 940 950 960
G C C C T A T A G T G A G T C G T A T T A C A A T T C A C T G G C C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T C G C C A G C T G G C G
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T A A T A G C G A A G A G G C C C G C A C C G A T C G C C C T T C C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T T G T G G A T G T A C A
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
G A G T G A T A T T A T T G A C A C G C C G G G G C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A A A A A A A G T C T C C C G T G A A C T T T A C C C G G G G N NG C A T A T C G G G G A TG A A A G C T G
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (6071), C (2946), G (2996), T (5487)





Figure A26 DNA sequencing from genotyping of 3’ integration of KAHRP2 transgenic parasites (clone. 3’ K6)                    
10 20 30 40 50 60 70 80 90 100 110 120
A N N N NN T T N N N N TN N N N NN T T N N N N N NGN N NN A A C GT N A A A T N N A AN N N N A T N N T N T T N A A A A T C C T A A T T T N N T T N N T A A T T A T A A T T T T A T A C A C A T A A T A T A T A T A T A T A T A T A T A T
130 140 150 160 170 180 190 200 210 220 230 240
A T A T A T A T A T A T G C A T A T A C T T G T T T T C C T T A T A T T T A T G C T T A A A T A C G T C T T A A T A A A A A A A A A T A A A A T A T G T T A A A A T G A T T G T A A T C A A A A T C T T A T A T T T A A T T A A C A T A T T T T
250 260 270 280 290 300 310 320 330 340 350 360
T A T T C T A C A T T C T T T C A A T A T A A T T T T C A T T T A T A T T A A T G T T T C T T T T T T A T A T T A A G A T T T T A T T T G A T T T T C T C T A T T C A T A T A A T A T A T T A T C T A T A C C T T C G A A G T A T A T T T T A A
370 380 390 400 410 420 430 440 450 460 470 480
A A A A A T A T A T A T T T A T T G G T A T A T C T T T C T A A T T C A A A A A G T A A T T A T A T T T T A T G A A T C A A C T G C A G A G A T T A T T T A A C C A C A G C A T C C T C T T T T C T T C T T T T T C T T T C C T G C T T C T T G
490 500 510 520 530 540 550 560 570 580 590 600
T A A T T G T G C T T G T C C T C T T G A C A T T A C T T G T T C A C C A T T A T T T G C A G C A T T T T T A T C G G C A G T T T C A T C T T T A G A T T G T A C T G C A T T A G C T C C T G T A G T T G C T C C T G T A G T T G A A C C T G C
610 620 630 640 650 660 670 680 690 700 710 720
A G T A G T A C T T G C T C C T T T A G T T G C T C C T T C A G T A G T A C T T G C T T C T T T A G T T G C T C C T T T A G A A G T A C T T G C T A A T T C T A G A T T T A A T A A A T A T G T T C T T A T A T A T A A T G A G A A A T A A A T
730 740 750 760 770 780 790 800 810 820 830 840
A T T T A A C A T A T G T T T A A A A A G A A A A A T T T A A G A T T T A C A T G A T T A G G A A T A A A A A T A T T A A A A G C T A T A T A T T A A T G T T G T A C T T T A T A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C
850 860 870 880 890 900 910 920 930 940 950 960
G C C C T A T A G T G A G T C G T A T T A C A A T T C A C T G G C C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T C G C C A G C T G G C G
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T A A T A G C G A A G A G G C C C G C A C C G A T C G C C C T T C C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T T G T G G A T G T A C A
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
G A G T G A T A T T A T T G A C A C G C C G G G G C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A G A T A A A G T C T C C C G T G A A C T T T A C C C G G G G G G N C A T A T C G G G G A A G A A A G C T G
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (6571), C (3712), G (2560), T (8175)





Figure A27 DNA sequencing from genotyping of 5’ integration of UMP-CMP kinase transgenic parasites (PCR product of 5’ UMP) 
10 20 30 40 50 60 70 80 90 100 110 120
T T C A G A A C A A G G A T A C T T T A T G A T T A C C A A A G T T A T T T T T A A T A T T T T T T T T T A TG T T C T A G T A A A A A AT C C A T A T T T A GT T A GT C G A A A A T T T C T A C C T T T T A A A A A A T A G C A A G C A T T
130 140 150 160 170 180 190 200 210 220 230 240
T T C C T T T T T A C A T A A A T A G A A C T A A T G G T T C T T A T A A A A A G G A A C A A C C T T T T A A A A T T G A A A G C C A A C A T T A T A A T A A A A T A A C A A G A A A A T T T T A T A A A T T T A A G A A A A A T A T A T A C A
250 260 270 280 290 300 310 320 330 340 350 360
C A T C T A C A T C A A A C T T T T C T A T A A A C A G T T A T A A T A T T T G G G A A A A A C A A T T T T T A A G C A T T T T G T A A A A A A A A T T A A A A T A T A T T T A T A T A A T A T T A T T T T A T T T T A T T A T A T A T T A T A
370 380 390 400 410 420 430 440 450 460 470 480
T T A T T T T T A T T T T T A T T T T T T T T T T T T T T T C T C T A C A A A T T T T A T C T A T T G G T T T A T T A T A A A A A T A T C T A T T T C T A A T A A T A A A T A A T T A A A A T A T C A T T T T A T A A A A A C A A A A G T A T C




Signal: A (9252), C (5274), G (3885), T (13864)





Figure A28 DNA sequencing from genotyping of 3’ integration of UMP-CMP kinase transgenic parasites (clone. 3’ U1) 
10 20 30 40 50 60 70 80 90 100 110 120
N NN N NN N N NN N N T T AA A N A A N T N G C N N T T A A C T A T A A A A A G G G T A C G A A G G T A C A A T T A T A T A T T T T A A A G A C A A T T A A A A A T A A A A A A T A A A A A A T A A A T G A C A T A A A A T A A A A A A A A A
130 140 150 160 170 180 190 200 210 220 230 240
T A T A C A T A A A T A T A A A T A C A T A T A A T A T A T A T A A T A T A T A T A T A A T T A A A A A C A T T G T T T G G G G G A A A A A A A A A G T A A A T T A T T T A A C C C T A A A C C T T G A A C A A C T T A T T A C A T A T T T G T
250 260 270 280 290 300 310 320 330 340 350 360
A A A A A C A T A C T G A A T A T C A C T C C A A A C G T C T T G A A T A T T T T T A T T T G C A T T A A T A A A A A T G C A T T T G T T T T C A T T T A A A A A T A A A T T T A T T A T A G G A A T A C A A T C A T T A T T A T G A G T A T C
370 380 390 400 410 420 430 440 450 460 470 480
A A A T C G T T T T T T T A A T G T A T C C A T A T T A T C A T C T A C T C T T C C T A C A T A T A C A A A A A A T T A T A A A C A C A C A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T A T A T T A A A A T A T A T A A
490 500 510 520 530 540 550 560 570 580 590 600
T T T T T T T T T T T T T T T T T G T T T G T T T C G G A T T C A T T A A A T T C T T A C C A C A A G T T A A T C C T C T A T T C A T A C A T C T C T C T A T C A T T A T C T C T T C A T C A C A A T A T A A A A A T A A A C A T A A A T G T A
610 620 630 640 650 660 670 680 690 700 710 720
C A T A T G C A T A A T T T C C T A T T A T A T T A A T C C A T C C T G A T C A A A T T C T A G A T T T A A T A A A T A T G T T C T T A T A T A T A A T G A G A A A T A A A T A T T T A A C A T A T G T T T A A A A A G A A A A A T T T A A G A
730 740 750 760 770 780 790 800 810 820 830 840
T T T A C A T G A T T A G G A A T A A A A A T A T T A A A A G C T A T A T A T T A A T G T T G T A C T T T A T A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C G C C C T A T A G T G A G T C G T A T T A C A A T T C A C T G G C
850 860 870 880 890 900 910 920 930 940 950 960
C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T C G C C A G C T G G C G T A A T A G C G A A G A G G C C C G C A C C G A T C G C C C T T C
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T T G T G G A T G T A C A G A G T G A T A T T A T T G A C A C G C C G G GG C A A C GG A T
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A G A T A A A G T C T C C C G T G A A C T T T A C C C G G NN G G N G C A T A T C G G G G A T G A A A G C T G G N G C A T G A T G A C C A C C G A A N T G G C C CA G G N T G
1210 1220 1230 1240




Signal: A (1076), C (514), G (536), T (1585)





Figure A29 DNA sequencing from genotyping of 5’ integration of DTC transgenic parasites (clone. 5’ D8)  
10 20 30 40 50 60 70 80 90 100 110 120
N N N N TN A N N A T T C G C C T N N N N NNT N NT N N NN N N N N NN N A A N N NN N T N T N N A T N N T T N A T T N T N N G A A AT A G A T A T T T T T A T A A T A A A C C A A T A G A T A A A A T T T G T A G A G A A A A A A A A A T A
130 140 150 160 170 180 190 200 210 220 230 240
A A A A T A A A A A T A A A A A T A A T A T A A T A T A T A A T A A A A T A A A A T A A T A T T A T A T A A A T A T A T T T T A A T T T T T T T T A C A A A A T G C T T A A G T T C T C C T T C T T T T T T T A C C A T G T C T G A A A A A G T
250 260 270 280 290 300 310 320 330 340 350 360
A C G A A A T A A T C C T A A T C G A C C A G T A G T A T A A A T A A C T T G A C G A G T T A A T C C A G C A T C T A A T C C T T T A T A T A A T G A C A A A A A T C C T T C A T T C T T T A T T A T G T C C T T A G C A A C T A T A A A T G G
370 380 390 400 410 420 430 440 450 460 470 480
A T T C C T T A A T A C A T T T T T T C C T T C A G C A T T T A A T T G A A T T C T T A C T T T T A C C A T A T C T A A T G G T T G G A T A C A A A A T G T G G C A A A C A T A C C A C T T G C T C C T C C T A C T G C G A A T G G T T T T A T
490 500 510 520 530 540 550 560 570 580 590 600
C T T T T C A A A A A C A C T C T T G T T A T T A T T C C C C T T T T T A T T A A C A T C A A C A C T T G A A C T T G A T T C T A A A T C A T A T T T A G C T A T A T C T C T G T C C A T C T T A T A A A T A T A T A T A T A T A T A T A T T A
610 620 630 640 650 660 670 680 690 700 710 720
A T A C G T T C A C A A T T T T A T T T A A T C A T A C A T A T A T T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T A T T T T T A T T T A C A T G T G T T A G G T A A G G A A T A T T A T A A G G G C G A A T T C G C G G C C G C
730 740 750 760 770 780 790 800 810 820 830 840
T A A A T T C A A T T C G C C C T A T A G T G A G T C G T A T T A C A A T T C A C T G G C C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T
850 860 870 880 890 900 910 920 930 940 950 960
C G C C A G C T G G C G T A A T A G C G A A G A G G C C C G C A C C G A T C G C C C T T C C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
T G T G G A T G T A C A G A G T G A T A T T A T T G A C A C G C C G G G G C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A G A T A A A G T C T C C C G T G A A C T T T A C C C G G T G G T G C A T A T C G G
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
G G A T G A A A G C T G G C G C A T G A T G A C C A C C G A T A T G G C C A G T G T G C C G G T C T C C G T T A T C G G G G A A G A A G T G G C T G A T C T C A G C C A C C G C G A A A A T G A C T T C A A A A A C G C C A T T A A C C T G A T
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (7053), C (3432), G (2807), T (7816)





Figure A30 DNA sequencing from genotyping of 3’ integration of DTC transgenic parasites (clone. 3’ DTC1) 
10 20 30 40 50 60 70 80 90 100 110 120
N N N N N T T A T T C C T A A T CA T G T A A A T C T T A A A T T T T T C T T T T T A A A CA T A T G T T A A A T A T T T A T T T C T CA T T A T A T A T A A G A A C A T A T T T A T T A A A T C T A G A A T T T G A T C A C C T G C A G A T T
130 140 150 160 170 180 190 200 210 220 230 240
T A T C T T T A A T T A G A T T A C A A G C T G A T A A T A C A T T A C C A A A A G A A T T A A A A A G G A A T T A T A C T G G T G T G T T T A A T G C A T T A T A T A G A A T T T C A A A A G A A G A A G G A T T A T T T G C T T T A T G G A
250 260 270 280 290 300 310 320 330 340 350 360
A A G G T T C G G T T C C A A C T A T A G C T A G A G C C A T G T C A T T A A A T T T A G G A A T G C T T T C T A C T T A T G A T C A A T C A A A A G A A T T T T T A C A A A A A T A T C T T G G T G T T G G T A T G A A G A C T A A T C T G G
370 380 390 400 410 420 430 440 450 460 470 480
T T G C T A G T G T T A T T A G T G G C T T T T T T G C G G T C A C T T T A A G T T T A C C T T T T G A T T T T G T T A A A A C T T G C A T G C A A A A A A T G A A A G C A G A T C C T G T T A C T A A G A A A A T G C C C T A T A A A A A T A
490 500 510 520 530 540 550 560 570 580 590 600
T G T T A G A T T G T T C T A T T C A A T T A T A T A A A A A A G G A G G T A T C T C T A T T T T C T A T T C A A G T T A T G C T A C C T A T T A T G T A C G T A T C G C A C C T C A T G C T A T G A T T A C A C T C A T A A C T G T A G A T T
610 620 630 640 650 660 670 680 690 700 710 720
A T C T A A A T A A T C T T T T A A A A A A A A T T T C T T A A C T T G A T T A C A C A A C C A C A A G T A A T T A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C G C C C T A T A G T G A G T C G T A T T A C A A T T C A C T G
730 740 750 760 770 780 790 800 810 820 830 840
G C C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T C G C C A G C T G G C G T A A T A G C G A A G A G G C C C G C A C C G A T C G C C C T
850 860 870 880 890 900 910 920 930 940 950 960
T C C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T T G T G G A T G T A C A G A G T G A T A T T A T T G A C A C G C C G G G G C G A C G G
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A G A T A A A G T C T C C C G T G A A C T T T A C C C G G T G G T G C A T A T C G G G G A T G A A A G C T G G C G C A T G A T G A C C A C C G A T A T G G C C A G T G T G
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
C C G G T C T C C G T T A T C C G G G G A A G A A A G T G G C T G A T C T C A G C C A C C G C G A A A A T G A C A T C A A A A A CG C C A T T A A C C T G A T G T T C T G G G G A A N N T A A A T G T C A G G C A T G A A A T T A T C A A A A A
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (3684), C (2437), G (2845), T (5073)





Figure A31 DNA sequencing from genotyping of 3’ integration of DTC transgenic parasites (clone. 3’ DTC2) 
10 20 30 40 50 60 70 80 90 100 110 120
C N N N N N N T T A T T N N T A A T CA T G T A A A T C T T A A A T T T T T C T T T T T A A A CA T A T G T T A A A T A T T T A T T T C T CA T T A T A T A T A A G A A C A T A T T T A T T A A A T C T A G A A T T T G A T C A C C T G C A G A
130 140 150 160 170 180 190 200 210 220 230 240
T T T A T C T T T A A T T A G A T T A C A A G C T G A T A A T A C A T T A C C A A A A G A A T T A A A A A G G A A T T A T A C T G G T G T G T T T A A T G C A T T A T A T A G A A T T T C A A A A G A A G A A G G A T T A T T T G C T T T A T G
250 260 270 280 290 300 310 320 330 340 350 360
G A A A G G T T C G G T T C C A A C T A T A G C T A G A G C C A T G T C A T T A A A T T T A G G A A T G C T T T C T A C T T A T G A T C A A T C A A A A G A A T T T T T A C A A A A A T A T C T T G G T G T T G G T A T G A A G A C T A A T C T
370 380 390 400 410 420 430 440 450 460 470 480
G G T T G C T A G T G T T A T T A G T G G C T T T T T T G C G G T C A C T T T A A G T T T A C C T T T T G A T T T T G T T A A A A C T T G C A T G C A A A A A A T G A A A G C A G A T C C T G T T A C T A A G A A A A T G C C C T A T A A A A A
490 500 510 520 530 540 550 560 570 580 590 600
T A T G T T A G A T T G T T C T A T T C A A T T A T A T A A A A A A G G A G G T A T C T C T A T T T T C T A T T C A A G T T A T G C T A C C T A T T A T G T A C G T A T C G C A C C T C A T G C T A T G A T T A C A C T C A T A A C T G T A G A
610 620 630 640 650 660 670 680 690 700 710 720
T T A T C T A A A T A A T C T T T T A A A A A A A A T T T C T T A A C T T G A T T A C A C A A C C A C A A G T A A T T A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C G C C C T A T A G T G A G T C G T A T T A C A A T T C A C
730 740 750 760 770 780 790 800 810 820 830 840
T G G C C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T C G C C A G C T G G C G T A A T A G C G A A G A G G C C C G C A C C G A T C G C C
850 860 870 880 890 900 910 920 930 940 950 960
C T T C C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T T G T G G A T G T A C A G A G T G A T A T T A T T G A C A C G C C G G G G C G A C
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A G A T A A A G T C T C C C G T G A A C T T T A C C C G G T G G T G C A T A T C G G G G A T G A A A G C T G G C G C A T G A T G A C C A C C G A T A T G G C C A G T G
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
T G C C G G T C T C C G T T A T C CG G G G A A N A A G T G G C T G A T C T C A G C C A C C G C G A A A A T G A C A T C A A A A C G C C A T T A A C C T G A T G T T C T G G G G A A N N A A A T G T C A G G C A T G A A A T T A T C A A A A A G
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (4560), C (2716), G (3322), T (5918)





Figure A32 DNA sequencing from genotyping of 3’ integration of DTC transgenic parasites (clone. 3’ DTC3) 
10 20 30 40 50 60 70 80 90 100 110 120
N N NN NNN N N TT A N N A N T C G C CC T T A T T CC T A A T CA T G T A A A T C T T A A A T T T T T C T T T T T A A A C A T A T G T T A A A T A T T T A T T T C T C A T T A T A T A T A A G A A C A T A T T T A T T A A A T C T A G A A T
130 140 150 160 170 180 190 200 210 220 230 240
T T G A T C A C C T G C A G A T T T A T C T T T A A T T A G A T T A C A A G C T G A T A A T A C A T T A C C A A A A G A A T T A A A A A G G A A T T A T A C T G G T G T G T T T A A T G C A T T A T A T A G A A T T T C A A A A G A A G A A G G
250 260 270 280 290 300 310 320 330 340 350 360
A T T A T T T G C T T T A T G G A A A G G T T C G G T T C C A A C T A T A G C T A G A G C C A T G T C A T T A A A T T T A G G A A T G C T T T C T A C T T A T G A T C A A T C A A A A G A A T T T T T A C A A A A A T A T C T T G G T G T T G G
370 380 390 400 410 420 430 440 450 460 470 480
T A T G A A G A C T A A T C T G G T T G C T A G T G T T A T T A G T G G C T T T T T T G C G G T C A C T T T A A G T T T A C C T T T T G A T T T T G T T A A A A C T T G C A T G C A A A A A A T G A A A G C A G A T C C T G T T A C T A A G A A
490 500 510 520 530 540 550 560 570 580 590 600
A A T G C C C T A T A A A A A T A T G T T A G A T T G T T C T A T T C A A T T A T A T A A A A A A G G A G G T A T C T C T A T T T T C T A T T C A A G T T A T G C T A C C T A T T A T G T A C G T A T C G C A C C T C A T G C T A T G A T T A C
610 620 630 640 650 660 670 680 690 700 710 720
A C T C A T A A C T G T A G A T T A T C T A A A T A A T C T T T T A A A A A A A A T T T C T T A A C T T G A T T A C A C A A C C A C A A G T A A T T A A G G G C G A A T T C G C G G C C G C T A A A T T C A A T T C G C C C T A T A G T G A G T
730 740 750 760 770 780 790 800 810 820 830 840
C G T A T T A C A A T T C A C T G G C C G T C G T T T T A C A A C G T C G T G A C T G G G A A A A C C C T G G C G T T A C C C A A C T T A A T C G C C T T G C A G C A C A T C C C C C T T T C G C C A G C T G G C G T A A T A G C G A A G A G G
850 860 870 880 890 900 910 920 930 940 950 960
C C C G C A C C G A T C G C C C T T C C C A A C A G T T G C G C A G C C T A T A C G T A C G G C A G T T T A A G G T T T A C A C C T A T A A A A G A G A G A G C C G T T A T C G T C T G T T T G T G G A T G T A C A G A G T G A T A T T A T T G
970 980 990 1000 1010 1020 1030 1040 1050 1060 1070 1080
A C A C G C C G G G G C G A C G G A T G G T G A T C C C C C T G G C C A G T G C A C G T C T G C T G T C A G A T A A A G T C T C C C G T G A A C T T T A C C C G G T G G T G C A T A T C G G G G G A T G A A A G C T G G C G C A T G A T G A C C
1090 1100 1110 1120 1130 1140 1150 1160 1170 1180 1190 1200
A C C G A T A T G G C C A G T G T G C C G G T C T C C G T T A T C GG G G G A A G A A AG T G G C T G A T C T C A G C C A C C G C G A A A A T G A C A T C A A A A A C G C C A T T A A C C T G A T G T T C T G G G G G A T N N A A A T G T C A G
1210 1220 1230 1240 1250 1260 1270 1280 1290 1300 1310 1320




Signal: A (4294), C (2515), G (3548), T (5241)
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